<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58997</article-id><article-id pub-id-type="doi">10.7554/eLife.58997</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-192214"><name><surname>Chen</surname><given-names>Chuyu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5666-5173</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192215"><name><surname>Soto</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209092"><name><surname>Dumrongprechachan</surname><given-names>Vasin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5890-6778</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192216"><name><surname>Bannon</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192283"><name><surname>Kang</surname><given-names>Shuo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-45086"><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3710-1484</contrib-id><email>Yevgenia.Kozorovitskiy@northwestern.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-163394"><name><surname>Parisiadou</surname><given-names>Loukia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2569-4200</contrib-id><email>loukia.parisiadou@northwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Pharmacology, Feinberg School of Medicine, Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Neurobiology, Northwestern University</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Huguenard</surname><given-names>John R</given-names></name><role>Senior Editor</role><aff><institution>Stanford University School of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Lupica</surname><given-names>Carl</given-names></name><role>Reviewing Editor</role><aff><institution>National Institute on Drug Abuse, National Institutes of Health</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>02</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e58997</elocation-id><history><date date-type="received" iso-8601-date="2020-05-16"><day>16</day><month>05</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-10-01"><day>01</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Chen et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Chen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-58997-v2.pdf"/><abstract><p>LRRK2 is a kinase expressed in striatal spiny projection neurons (SPNs), cells which lose dopaminergic input in Parkinson’s disease (PD). R1441C and G2019S are the most common pathogenic mutations of LRRK2. How these mutations alter the structure and function of individual synapses on direct and indirect pathway SPNs is unknown and may reveal pre-clinical changes in dopamine-recipient neurons that predispose toward disease. Here, R1441C and G2019S knock-in mice enabled thorough evaluation of dendritic spines and synapses on pathway-identified SPNs. Biochemical synaptic preparations and super-resolution imaging revealed increased levels and altered organization of glutamatergic AMPA receptors in LRRK2 mutants. Relatedly, decreased frequency of miniature excitatory post-synaptic currents accompanied changes in dendritic spine nano-architecture, and single-synapse currents, evaluated using two-photon glutamate uncaging. Overall, LRRK2 mutations reshaped synaptic structure and function, an effect exaggerated in R1441C dSPNs. These data open the possibility of new neuroprotective therapies aimed at SPN synapse function, prior to disease onset.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Parkinson’s disease is caused by progressive damage to regions of the brain that regulate movement. This leads to a loss in nerve cells that produce a signaling molecule called dopamine, and causes patients to experience shakiness, slow movement and stiffness. When dopamine is released, it travels to a part of the brain known as the striatum, where it is received by cells called spiny projection neurons (SPNs), which are rich in a protein called LRRK2. Mutations in this protein have been shown to cause the motor impairments associated with Parkinson’s disease.</p><p>SPNs send signals to other regions of the brain either via a ‘direct’ route, which promotes movement, or an ‘indirect’ route, which suppresses movement. Previous studies suggest that mutations in the gene for LRRK2 influence the activity of these pathways even before dopamine signaling has been lost. Yet, it remained unclear how different mutations independently affected each pathway. To investigate this further, Chen et al. studied two of the mutations most commonly found in the human gene for LRRK2, known as G2019S and R1441C. This involved introducing one of these mutations in to the genetic code of mice, and using fluorescent proteins to mark single SPNs in either the direct or indirect pathway.</p><p>The experiments showed that both mutations disrupted the connections between SPNs in the direct and indirect pathway, which altered the activity of nerve cells in the striatum. Chen et al. found that individual connections were more strongly affected by the R1441C mutation. Further experiments showed that this was caused by the re-organization of a receptor protein in the nerve cells of the direct pathway, which increased how SPNs responded to inputs from other nerve cells.</p><p>These findings suggest that LRRK2 mutations disrupt neural activity in the striatum before dopamine levels become depleted. This discovery could help researchers identify new therapies for treating the early stages of Parkinson’s disease before the symptoms of dopamine loss arise.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>striatum</kwd><kwd>LRRK2</kwd><kwd>dendritic spine</kwd><kwd>parkinson's disease</kwd><kwd>AMPAR</kwd><kwd>excitatory synapse</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R01NS097901</award-id><principal-award-recipient><name><surname>Parisiadou</surname><given-names>Loukia</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000864</institution-id><institution>Michael J. Fox Foundation for Parkinson's Research</institution></institution-wrap></funding-source><award-id>LRRK2 Challenge</award-id><principal-award-recipient><name><surname>Parisiadou</surname><given-names>Loukia</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R01NS107539</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001447</institution-id><institution>Rita Allen Foundation</institution></institution-wrap></funding-source><award-id>Rita Allen Scholar Award</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005665</institution-id><institution>Kinship Foundation</institution></institution-wrap></funding-source><award-id>Searle Scholar Award</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000997</institution-id><institution>Arnold and Mabel Beckman Foundation</institution></institution-wrap></funding-source><award-id>Beckman Young Investigator Award</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>F32NS103243</award-id><principal-award-recipient><name><surname>Bannon</surname><given-names>Nicholas</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>19PRE3438005</award-id><principal-award-recipient><name><surname>Dumrongprechachan</surname><given-names>Vasin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Although human Parkinson's disease is linked to dopamine loss, two distinct mutations in a kinase associated with familial Parkinson's operate downstream, altering excitatory synapses on dopamine-sensing neurons.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Gain-of-function mutations in the leucine-rich repeat kinase 2 (<italic>LRRK2</italic>) gene represent the most common cause of familial Parkinson’s disease (PD) (<xref ref-type="bibr" rid="bib1">Alessi and Sammler, 2018</xref>). Carriers are at risk for late onset PD, which is clinically indistinguishable from sporadic PD, consistent with a possibility of common disease mechanisms (<xref ref-type="bibr" rid="bib25">Kluss et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Italian Parkinson's Genetics Network et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Haugarvoll et al., 2008</xref>; <xref ref-type="bibr" rid="bib10">Di Maio et al., 2018</xref>). <italic>LRRK2</italic> gene product is a large multi-domain protein with two catalytic domains: a GTPase (ROC-COR) domain and a serine/threonine-directed protein kinase domain. Pathogenic mutations are found predominantly in these two domains, suggesting that LRRK2 enzymatic activities are involved in PD pathogenesis (<xref ref-type="bibr" rid="bib6">Cookson, 2010</xref>), (<xref ref-type="bibr" rid="bib12">Esteves et al., 2014</xref>). Yet, how LRRK2 mutations in the two distinct functional domains contribute to PD pathogenesis and whether they act through a common mechanism is unknown. Enhanced LRRK2 kinase activity conferred by the G2019S (GS) mutation in the kinase domain is the most extensively studied property of mutant LRRK2 (<xref ref-type="bibr" rid="bib6">Cookson, 2010</xref>), (<xref ref-type="bibr" rid="bib49">Steger et al., 2016</xref>). Meanwhile, the R1441C (RC) substitution in the GTPase domain results in impaired GTP hydrolysis, which is thought to indirectly enhance kinase activity through mechanisms that remain to be determined (<xref ref-type="bibr" rid="bib34">Nguyen and Moore, 2017</xref>), (<xref ref-type="bibr" rid="bib65">Xiong et al., 2010</xref>).</p><p>Despite remaining questions, the last decade marks extensive progress in our understanding of LRRK2 function. This kinase is highly expressed in the spiny projection neurons (SPNs) of the striatum (<xref ref-type="bibr" rid="bib34">Nguyen and Moore, 2017</xref>; <xref ref-type="bibr" rid="bib61">West et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>). LRRK2 expression peaks in a developmental time window of extensive glutamatergic excitatory synapse formation, suggesting that LRRK2 may regulate the development or function of excitatory synaptic networks. Consistently, several lines of evidence suggest that loss of LRRK2 alters striatal circuits during postnatal development (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>), and the GS pathogenic mutation increases glutamatergic activity in cultured cortical neurons (<xref ref-type="bibr" rid="bib3">Beccano-Kelly et al., 2015</xref>) as well as in acute striatal slices (<xref ref-type="bibr" rid="bib32">Matikainen-Ankney et al., 2016</xref>), (<xref ref-type="bibr" rid="bib59">Volta et al., 2017</xref>). Recent studies assign a critical role of LRRK2 in presynaptic terminal vesicle function (<xref ref-type="bibr" rid="bib37">Pan et al., 2017</xref>). Here, the GS mutation impairs presynaptic glutamatergic release, suggested to underlie changes in glutamatergic activity of striatal neurons (<xref ref-type="bibr" rid="bib59">Volta et al., 2017</xref>). The potential postsynaptic function of LRRK2 remains less well-characterized. We have previously shown that the RC mutation impedes normal striatal protein kinase A (PKA) signaling, which in turn results in increased GluA1 phosphorylation in developing SPNs, consistent with a postsynaptic mechanism of action (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>). Similarly, glutamate receptor trafficking perturbations were observed in <italic>GS</italic> knock-in (KI) mice in response to plasticity induction protocols (<xref ref-type="bibr" rid="bib33">Matikainen-Ankney et al., 2018</xref>). Furthermore, although an increase in spontaneous excitatory postsynaptic currents has been reported for the dorsomedial striatum, a recent report failed to show this phenotype for the ventral striatum (<xref ref-type="bibr" rid="bib23">Huntley, 2020</xref>), despite LRRK2 expression in that region (<xref ref-type="bibr" rid="bib61">West et al., 2014</xref>), (<xref ref-type="bibr" rid="bib19">Giesert et al., 2013</xref>). These observations suggest that LRRK2 mutations may shape the corticostriatal synaptic function in a synapse-, cell- and area-specific manner. Overall, despite the links between LRRK2 and glutamatergic synapse dysfunction, the field currently lacks a coherent framework for understanding how the two distinct LRRK2 mutations selectively alter synaptic function in specific cell types.</p><p>Given the complementary role of direct and indirect striatal pathways in behavior (<xref ref-type="bibr" rid="bib28">Kravitz et al., 2010</xref>; <xref ref-type="bibr" rid="bib13">Fieblinger et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Kozorovitskiy et al., 2012</xref>) the lack of pathway specificity in prior studies limits our understanding of disease related mechanisms associated with LRRK2 mutations. Previous studies did not compare the dysfunction of two LRRK2 mutations which are found in distinct LRRK2 domains and confer divergent biochemical properties to the kinase, choosing instead to focus on the one mutation or the other. Earlier reports have mainly focused on the GS pathogenic mutation, and whether the molecular mechanisms underlying pathology across the two most common mutations remain unknown. In addition, the phenotype of LRRK2 mutant models is subtle and corresponds to a moderate susceptibility for PD. Therefore, refined tools are required to distinguish the early pre-pathology functional abnormalities. We have taken the approach of combining molecular, anatomical and electrophysiological approaches that capture global aspects of LRRK2 function in the striatum, but also single synapse-specific effects, in case abnormalities are associated with specific synapse subtypes.</p><p>Here, we undertook a systematic synapse function and structure analysis in two different mutant LRRK2 mouse lines to evaluate the contribution of this kinase mutations to SPN synapses across direct and indirect pathways. Using a combination of subcellular fractionation biochemistry, super-resolution imaging, and two-photon laser scanning microscopy with whole-cell physiology approaches, we found a critical role for LRRK2 RC, and to a lesser extent GS mutation, in organizing the structure and function of the SPN excitatory synapses, particularly for dSPNs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>LRRK2 <italic>+/RC</italic> mutation leads to increased synaptic incorporation of GluA1 in the striatum</title><p>In order to resolve LRRK2 mediated synaptic alterations in identified SPNs in a systematic way, we crossed the pathway-specific reporter BAC transgenic mice (<xref ref-type="bibr" rid="bib55">Tozzi et al., 2018a</xref>) with two mutant LRRK2 KI mouse lines. Specifically, <italic>Drd1-Tomato</italic> and <italic>Drd2-eGFP</italic> reporter mice were crossed with each of the two mutant LRRK2 lines (RC and GS) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). This platform enabled pathway-specific interrogation of each LRRK2 mutation side by side, as well as initial experiments described below that were done on aggregated SPN populations. Our previous findings showed that <italic>RC</italic> KI neurons displayed altered PKARIIβ localization, as compared to wild-type (+/+) neurons, suggesting altered synaptic PKA activity in SPNs (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>). To further explore the synaptic PKA signaling in both KI mouse lines, we employed differential centrifugation, discontinuous sucrose gradient, and detergent extractions to isolate synaptic subcellular fractions from striatal extracts as shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref> (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>), (<xref ref-type="bibr" rid="bib4">Bermejo et al., 2014</xref>; <xref ref-type="bibr" rid="bib39">Peng et al., 2004</xref>). Consistent with our previous data, PKA activity was found elevated in the P2 crude synaptosomal preparation of <italic>+/RC</italic> but not <italic>+/GS</italic> striatal extracts, when phospho-PKA substrate antibody was used to detect phosphorylation of downstream PKA targets. The increased PKA activity in <italic>+/RC</italic> was further confirmed by an increase in phosphorylation of GluA1, a key downstream target of PKA. To directly evaluate LRRK2 function, we examined the phosphorylation of two known targets of this kinase, Rab8A and Rab10. Phosphorylation of both targets was selectively increased in the synaptic fraction (P2) of the RC striatal extracts (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Notably, while Rab8A is a known physiological target of LRRK2 kinase activity (<xref ref-type="bibr" rid="bib49">Steger et al., 2016</xref>), (<xref ref-type="bibr" rid="bib5">Bonet-Ponce and Cookson, 2019</xref>), it was unclear whether this is the case in the striatum, since only low levels of <italic>Rab8A</italic> transcripts are found in dSPNs and iSPNs at the single-cell level (<ext-link ext-link-type="uri" xlink:href="http://dropviz.org">dropviz.org</ext-link>) (<xref ref-type="bibr" rid="bib45">Saunders et al., 2018</xref>). Our finding stands in accordance with two recent studies in cell lines, showing that the RC and other mutations found in the GTPase domain of LRRK2 result in greater increase kinase activity, compared to the GS mutation (<xref ref-type="bibr" rid="bib43">Purlyte et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Liu et al., 2018</xref>). We further isolated the post-synaptic density (PSD) fraction from the P2 preparation by using a detergent extraction step. The PSD fraction showed enrichment of the postsynaptic marker PSD95, but not presynaptic protein synaptophysin (svp38) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Given that PKA mediated phosphorylation of S845 in GluA1 has a significant impact on synaptic trafficking of GluA1 (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>), (<xref ref-type="bibr" rid="bib44">Roche et al., 1996</xref>), we examined the levels of GluA1 in the PSD fractions of KI mice. We observed a significant increase in the GluA1 levels in the PSD fraction from <italic>+/RC</italic>, but not <italic>+/GS</italic> mice, compared to wild-type control (<italic>+/RC</italic>: 47% increase of control; <italic>+/GS</italic>: 19% increase relative to control, one-way ANOVA p=0.0397, post-hoc tests as noted, n = 6 per group) (<xref ref-type="fig" rid="fig1">Figure 1E,F</xref>), which was paralleled by elevated PKA activity specifically in the PSD fractions in <italic>+/RC (+/RC</italic>, 167% of control, one-way ANOVA p=0.0486, post-hoc tests as noted, n = 6) but not <italic>+/GS</italic> mice (<italic>+/GS</italic>, 118% of control, n = 6) (<xref ref-type="fig" rid="fig1">Figure 1E,G</xref>). Next, we determined the relative levels of PSD-95 protein in the PSD fraction across genotypes, which was used in the ratios in <xref ref-type="fig" rid="fig1">Figure 1F,G</xref>. We run subcellular fractions of all genotypes on the same blot (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>), and normalized PSD95 to another synaptic protein, Homer1. PSD95 band intensities across fractions and genotypes showed no difference. Furthermore, PSD95 band intensities in each of S1, P2, and PSD fractions were expressed as percentage of the PSD95 intensity of the wild type in each fraction (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Similarly, no differences in PSD95 levels in mutant LRRK2 fractions were observed after one-way ANOVA. Overall, our data show increased GluA1 levels in the PSD fractions of <italic>+/RC</italic> striatal extracts, which parallels enhanced synaptic PKA signaling.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>LRRK2 RC mutation increases synaptic glutamate receptor content in the striatum.</title><p>(<bold>A</bold>) Schematic diagram of LRRK2 protein highlighting the armadillo repeats (ARM), ankyrin (ANK) repeats, Ras of complex (ROC), C-terminal of ROC (COR), kin (KIN), and WD40 domains. Knock- in mice expressing the R1441C and G2019S mutations found in the ROC and kinase domains respectively, crossed with either <italic>Drd1-Tomato</italic> or <italic>Drd2-eGFP</italic> mouse lines. (<bold>B</bold>) Workflow schematic for subcellular fractionation of striatal homogenate for the enrichment of postsynaptic density fraction (PSD). (<bold>C</bold>) Representative western blot analysis of the subcellular fractionation results, showing supernatant (S1), crude synaptosomal preparation (P2), PSD, and Triton soluble fractions (TSF). (<bold>D</bold>) Western blot analysis of <italic>+/+, +/RC</italic>, and <italic>+/GS</italic> P2 striatal fractions probed for p-PKA substrates, pS845 GluA1, total GluA1, pT72Rab8A, total Rab8A, pT73Rab10, total Rab10, and PSD95. (E) Western blot analysis of <italic>+/+</italic>, <italic>+/RC</italic>, and <italic>+/GS</italic> mice probed for GluA1, p-PKA, and PSD95. S1 and PSD fractions are shown. (<bold>F-G</bold>) Quantification of GluA1 and p-PKA proteins in PSD fractions normalized to PSD95. Summary graphs reflect the mean, error bars reflect SEM. *p&lt;0.05, Tukey post-hoc test following one-way ANOVA.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Numerical data of the graphs in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>LRRk2 mutations do not alter PSD95 levels.</title><p>(<bold>A–B</bold>) Supernatant (S1), crude synaptosomal preparation (P2), PSD, and Triton soluble fractions (TSF) of wild type, +/RC and +/GS striata were run on the same blot. Ponceau staining shows similar loading across genotypes at a given fraction. Western blot analysis of the fractions described in <bold>A</bold>, probed for PSD95 and Homer-1. (<bold>C</bold>) Quantification of PSD95 band intensities normalized to Homer-1. Summary graphs represent the mean, while error bars SEM. (<bold>D</bold>) Quantification of PSD95 band intensities expressed as a fraction of the intensity of PSD95 wild type in each one of the S1, P2, and PSD fractions.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Numerical data of the graphs in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Altered nanoscale organization in the dendritic spines of direct and indirect pathway mutant LRRK2 SPNs</title><p>To precisely examine the nanoscale organization of GluA1 receptors in the dendritic spines of identified SPNs in mutant LRRK2 mice, we used structured illumination microscopy (SIM). SIM is able to overcome the resolution limits of conventional microscopy, and recently revealed a high degree of organization among scaffold proteins and AMPA receptors, forming nanoscale subsynaptic domains (<xref ref-type="bibr" rid="bib15">Gao et al., 2018</xref>; <xref ref-type="bibr" rid="bib8">Crosby et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Smith et al., 2014</xref>). Primary cultured striatal neurons from <italic>Drd1-dTomato</italic> or <italic>Drd2-eGFP</italic> mice crossed with either +/<italic>RC</italic> or +/<italic>GS</italic> mouse lines (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), were immunostained for GluA1 and PSD95 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, and <xref ref-type="fig" rid="fig3">Figure 3A–B</xref>, <xref ref-type="video" rid="fig2video1">Figure 2—video 1</xref>). We found several lines of evidence demonstrating increased synaptic incorporation of GluA1 in <italic>+/RC</italic> dSPNs, compared to <italic>+/+</italic> ones. Specifically, the distance between GluA1 and PSD95 was smaller in <italic>+/RC</italic> dSPNs compared to control dSPNs, while no difference was observed between <italic>+/GS</italic> and <italic>+/+</italic> neurons (+/RC, 63% of control, +/GS 85% of control one-way ANOVA, p=0.0208, post-hoc tests as noted, n = 75–93 dendritic spines/genotype) (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>). Similarly, the <italic>+/RC</italic> dendritic spines showed the greatest shift in cumulative distribution for minimum distance between GluA1 and PSD95 nanodomains (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). While the overlap area of GluA1 and PSD95 nanodomains was found elevated in the dendritic spines of <italic>+/RC</italic> dSPNs, no differences were observed in <italic>+/GS</italic> neurons, compared to <italic>+/+</italic> neurons (<italic>+/RC</italic>, 137% of control, +/GS, 102% of control one-way ANOVA p=0.0215, post hoc tests as noted, n = 75–93 dendritic spines/genotype) (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Similarly, the cumulative distribution analysis showed that GluA1-PSD95 distance was shifted towards higher values in the <italic>+/RC</italic> dSPNs (<xref ref-type="fig" rid="fig2">Figure 2G</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>LRRK2 RC mutation restructures the nanoscale synaptic organization of dSPNs.</title><p>(<bold>A</bold>) Schematic depicting experimental design. (<bold>B</bold>) Structured Illumination super-resolution microscopy (SIM) image of dendritic spines on +<italic>/+, +/RC</italic>, and <italic>+/GS Drd1-Tomato</italic> expressing SPNs, labeled with antibodies to GluA1 (purple), and PSD95 (green). Open arrowheads, GluA1 nanodomains; arrowheads, PSD95 nanodomains. (<bold>C</bold>) Schematic diagram and object masks depicting GluA1, PSD95, and overlap nanodomains within a dendritic spine. Minimum distance between GluA1-PSD95 is measured from the closest edge of the two nanodomains, as shown. (<bold>D, E</bold>) Summary graphs and cumulative distribution of the minimum distance between GluA1 and PSD95 nanodomains. (<bold>F, G</bold>) Summary data and cumulative frequency for the overlap area of GluA1 and PSD95 nanodomains within dendritic spines. Asterisk in D and F reflect statistical significance for Tukey’s multiple comparison tests after one-way ANOVA, whereas asterisks in E and G show statistical significance for Bonferroni post-hoc comparisons after Kolmogorov-Smirnov tests. (<bold>H</bold>) Bar graphs showing the ratio of GluA1-PSD95 overlap area in E relative to PSD95 area, across genotypes. Data are represented as mean ± SEM. (<bold>I-K</bold>) Correlation plots of overlap in GluA1-PSD95 area versus PSD95 area for +<italic>/+, +/RC</italic>, and <italic>+/GS Drd1-Tomato</italic> expressing SPNs. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw data plotted in graphs in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>LRRK2 mutations alter postsynaptic density area of SPNs.</title><p>(<bold>A</bold>) Summary graph, PSD95 area across genotypes of dSPNs. Error bars reflect SEM. (<bold>B</bold>) Cumulative percentage of PSD95 area per dendritic spine across dSPN genotypes. (<bold>C</bold>) Summary graph, PSD95 area across genotypes of iSPNs. Error bars reflect SEM; asterisks, Tukey post-hoc comparisons after one-way ANOVA, <italic>+/+</italic> vs. <italic>+/GS p&lt;0.001</italic> (<bold>D</bold>) Cumulative percentage of PSD95 areas per dendritic spine across iSPN genotypes.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Numerical data of the graphs in <xref ref-type="fig" rid="fig1s1">Figure 2—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig2-figsupp1-v2.tif"/></fig><media id="fig2video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-58997-fig2-video1.mp4"><label>Figure 2—video 1.</label><caption><title>3D Reconstruction of dendritic spine of an RC dSPN.</title><p>GluA1 (purple), and PSD95 (green), overlap area (white), as in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. A surface mask is added for a fraction of the video, enabling the visualization of GluA1 and PSD95 in spine head.</p></caption></media></fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>LRRK2 mutations alter the nanoscale synaptic organization of iSPNs.</title><p>(<bold>A</bold>) SIM image of <italic>+/+, +/RC</italic>, and <italic>+/GS</italic> Drd2-eGFP expressing SPNs immunostained with GluA1 (purple), and PSD95 (orange). Open arrowheads, GluA1 nanodomains; arrowheads, PSD95 nanodomains. GFP antibody was used to amplify the Drd2-eGFP signal. (<bold>B</bold>) Surface intensity through a dendritic spine head in an RC iSPN. (<bold>C</bold>) Schematic diagram and object masks depicting GluA1, PSD95, overlap nanodomains, and minimum distance between nanodomains within a dendritic spine head. (<bold>D</bold>) Bar graphs showing the minimum distance between GluA1 and PSD95 nanodomains. (<bold>E</bold>) Cumulative distribution of data shown in D. (<bold>F, G</bold>) Summary data and cumulative distribution of the overlap area between GluA1 and PSD95 nanodomains in dendritic spine heads across genotypes. Asterisks in F show statistical significance for Tukey’s multiple comparison tests after one-way ANOVA; asterisks in G reflect statistical significance for Bonferroni post-hoc comparisons after Kolmogorov-Smirnov tests. (<bold>H</bold>) The ratio of overlap area between GluA1 and PSD95 to the PSD95 area for +<italic>/+, +/RC</italic>, and <italic>+/GS</italic> iSPNs. (<bold>I-K</bold>) Correlation plots of overlap areas versus PSD95 area for iSPNs across genotypes. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Numerica data represented as graphs in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig3-v2.tif"/></fig><p>Given that the PSD95 area in <italic>+/GS</italic> dSPNs showed a trend towards decrease (+/RC, 94% of control, <italic>+/GS</italic>, 83% of control, one-way ANOVA p=0.0904, post-hoc +/+ vs +/GS p=0.075) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>), we evaluated the percentage of the GluA1-PSD95 overlap relative to the total PSD95 area across genotypes. 32% of total PSD95 area contained GluA1 in <italic>+/RC</italic> dSPNs, compared to 23% in <italic>+/+</italic> neurons, and 26% in <italic>+/GS</italic> neurons (one-way ANOVA p=0.0015, post hoc tests as noted) (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). These data strongly suggest increased levels of GluA1 at the synapses of +/RC dSPNs. Correlation analysis was performed to investigate the association between GluA1-PSD95 overlap nanodomain area and PSD95 area. A positive correlation was observed in all three genotypes (control, Spearman r = 0.5822, p-value&lt;0.0001, +/RC, r = 0.6522, p&lt;0.0001 and +/GS r = 0.6569, p-value&lt;0.0001). The correlation was stronger in LRRK2 mutant SPNs (<xref ref-type="fig" rid="fig2">Figure 2I–K</xref>).</p><p>A similar synaptic nanoscale organization analysis was performed for <italic>Drd2-eGFP</italic> control and mutant LRRK2 SPNs. The neurons were immunostained with GluA1 (purple), and PSD95 (orange) (<xref ref-type="fig" rid="fig3">Figure 3A–B</xref>) and minimum distance summary data (<italic>+/RC</italic>, 87% of control, <italic>+/GS</italic>, 89% of control, one-way ANOVA, p=0.6435 n = 72–88 dendritic spines/genotype), as well as cumulative distribution of the distance between the GluA1 and PSD95 nanodomains, showed no difference across genotypes (<xref ref-type="fig" rid="fig3">Figure 3C–D,E</xref>). We observed that the overlap GluA1 and PSD95 area was increased in <italic>+/GS</italic> SPNs (<italic>+/RC</italic>, 105% of control, <italic>+/GS</italic>, 155% of control, one-way ANOVA, p&lt;0.0001; post hoc tests as noted, p=72–88 dendritic spines/genotype) (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Further analysis showed an increase in the mean PSD95 area in the <italic>+/GS</italic> neurons (<italic>+/RC</italic>, 123% of control, <italic>+/GS</italic>, 137% of control, one-way ANOVA, p=0.0008, post hoc tests as noted) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>), as well as in cumulative frequency (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). However, the percentage of the total PSD95 area containing GluA1 nanodomains <italic>+/GS</italic> iSPNs compared to controls was similar (one-way ANOVA, p=0.469) (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Thus, the increased size of GluA1-PSD95 overlapping domains in the <italic>+/GS</italic> iSPNs reflects the elevated PSD95 area of these neurons (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C-D</xref>), and not synaptic GluA1 incorporation, as found in <italic>+/RC</italic>.</p><p>We aimed to further investigate the relationship between overlapping nanodomains size and PSD95 area in the iSPNs dendritic spines. In general, PSD95 area correlated with the overlap GluA1-PSD95 domain size in all genotypes (control, Spearman r = 0.7817, p&lt;0.0001, +/RC, r = 0.4040, p=0.0003 and +/GS, r = 0.7349, p&lt;0.0001) (<xref ref-type="fig" rid="fig3">Figure 3I–K</xref>). Based on <xref ref-type="fig" rid="fig2">Figure 2I</xref>, we found that for larger PSD95 domains, mutant LRRK2 dSPNs show a tendency towards larger overlap between GluA1 and PSD95. However, this was not the case for iSPNs of <italic>+/RC</italic> genotype. In fact, in <italic>+/RC</italic> iSPNs, some high overlap GluA1-PSD95 domains were characterized by smaller PSD95 areas. This detailed high-resolution imaging analysis points to different GluA1 subsynaptic distribution in the iSPNs of <italic>+/RC</italic> SPNs, compared to <italic>+/+</italic> and <italic>+/GS</italic>. Taken together, these single synapse imaging findings in pathway identified SPNs demonstrate an increased number of GluA1 receptors in the synapses of <italic>+/RC</italic> dSPNs, pointing toward cell type and mutant-specific LRRK2 functions. These observations suggest highly specific and likely regulated nanoscale organization of GluA1 receptors in SPN dendritic spines.</p></sec><sec id="s2-3"><title>Pathway-specific functional alterations in the synapses of R1441C and G2019S SPNs</title><p>Since the effects of LRRK2 mutations appear to alter excitatory synapse subunits, next we carried out recordings of pharmacologically isolated miniature excitatory post-synaptic currents (mEPSCs) in acute brain slices from mice of the three genotypes. SPN pathway identity was determined based on the presence or absence of <italic>Drd2-eGFP</italic> (<xref ref-type="bibr" rid="bib27">Kozorovitskiy et al., 2015</xref>). Neurons were held at −70 mV in voltage clamp, and pharmacologically isolated mEPSCs were recorded in the presence of tetrodotoxin (TTX). For dSPNs, the mean frequency of mEPSCs, averaged within each neuron, was decreased relative to controls for both LRRK2 mutations (GFP-, RC 60% of control, GS, 47% of control; two-way ANOVA, genotype main effect, p&lt;0.001, post-hoc tests as noted) (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). For iSPNs, lower mean frequency of mEPSCs, averaged within each neuron, was observed in both RC and GS neurons (GFP-, RC 60% of control, GS, 52% of control; two-way ANOVA, genotype main effect, p&lt;0.001, post-hoc tests as noted). In contrast to the mean frequency of mEPSCs, no significant differences in the mean within-cell response amplitude were observed across all six genotype/cell type combinations on post-hoc comparisons, despite a modest main effect of genotype (GFP-, RC 107% of control, GS, 92% of control; GFP+, RC 108% of control, GS 94% of control; two-way ANOVA, genotype main effect, p=0.041, N = 13–14 neurons/group) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). To evaluate the distribution of individual mEPSC features across genotypes, rather than within-neuron averages, we computed cumulative distributions of inter-event intervals (IEIs) and mEPSC amplitudes, along with histograms of response amplitudes (<xref ref-type="fig" rid="fig4">Figure 4D–E</xref>). Amplitude data were fitted with a gamma distribution, a non-negative asymmetrical distribution, because the mEPSC amplitudes were not normally or lognormally distributed (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), failing D'Agostino and Pearson, Shapiro-Wilk, and KS normality tests, p&lt;0.0001, for raw and log-transformed data. Skew and kurtosis across the 6 datasets were 2.19 ± 0.16 and 6.34 ± 0.1, respectively, appropriate the gamma distribution. Akaike information criterion (AIC) values as goodness-of-fit criteria confirmed superior fit of gamma family distribution over Gaussian. To compare the distributions of mEPSC amplitudes, we estimated mEPSC amplitude means across different genotypes for GFP- and GFP+ cell types using generalized linear modeling (GLM) with a gamma family distribution. mEPSC amplitudes in RC dSPNs were shifted toward larger events, and smaller events in GS dSPNs, with no differences in iSPNs (dSPNs, Bonferroni post-hoc comparisons, p&lt;0.0001; iSPNs, p&gt;0.7) (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Pathway-specific functional alterations of SPN synapses in LRRK2 mutants.</title><p>(<bold>A</bold>) Example miniature excitatory postsynaptic current (mEPSC) traces from individual neurons of six genotype-pathway combinations. GFP-, dSPNs; GFP+, iSPNs; color, as defined in the figure. Scale bars, 10 pA and 2.5 s. (<bold>B</bold>) Summary graph showing the frequency of pharmacologically isolated mEPSCs, in GFP- and GFP+ SPNs in controls, compared to both RC and GS mutations. Asterisks reflect statistical significance for Bonferroni post hoc comparisons after two-way ANOVA. (<bold>C</bold>) Same as B, but for mEPSC amplitude. (<bold>D</bold>) <italic>Left</italic>, cumulative distribution of inter-event intervals (IEI) for mEPSCs across genotypes for GFP- SPNs. <italic>Right</italic>, same as <italic>left</italic>, but for GFP+ SPNs. (<bold>E</bold>) Binned histograms and cumulative distribution of mEPSC amplitude data. X axis starts at 5 pA, reflecting the amplitude threshold for mEPSC identification. *p&lt;0.05, **p&lt;0.01.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw data of the graphs in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Analyses of mEPSC amplitude distributions.</title><p><italic>Left</italic>, gamma curve fits to density histogram of mEPSC amplitudes by genotype and cell type (bin width, 1 pA). Gamma AIC for GFP- controls +<italic>/+, +/RC</italic>, and <italic>+/GS</italic> was 11813, 7721, and 4920. Gamma AIC for GFP+ controls +<italic>/+, +/RC</italic>, and <italic>+/GS</italic> was 9477, 6825, and 4881. <italic>Right</italic>, overlaid gamma curve fits by genotype and cell type. (<bold>B</bold>) Amplitudes estimates from GLM using the gamma family of curves, 95% confidence intervals in blue. Bonferroni corrected post-hoc pairwise comparisons, GPF- neurons, ***p&lt;0.0001 for all comparisons; GFP+ neurons, p&gt;0.7.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Numerical data of <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Overall dendritic spine density and morphology is conserved in mutant LRRK2 SPNs</title><p>To investigate whether the observed decrease in the mEPSC frequency was associated with global changes in dendritic spine number and morphology, we relied on identifying pathway-specific SPNs by injecting a Cre-dependent adeno-associated virus (AAV) expressing eGFP virus (AAV8/Flex-GFP) in the striatum of neonatal pups. <italic>Drd1-Cre</italic> and <italic>Adora2a-Cre</italic> mice were crossed with <italic>+/RC</italic> and <italic>+/GS</italic> mice, as well as controls (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="video" rid="fig5video1">Figure 5—video 1</xref>). We then analyzed dendritic fragments of d- and iSPNs to determine dendritic spine density, spine head width, and spine length. No differences in any of these parameters were observed for all six genotype/cell type combinations (two-way ANOVA, n = 9–12 SPNs from 3 to 4 mice/genotype) (<xref ref-type="fig" rid="fig5">Figure 5B–E</xref>). Further dendritic spine classification showed no difference in dendritic spine type in SPNs of either pathway (two-way ANOVA, n = 9–14 SPNs for 3–4 mice/genotype) (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Overall, these data suggest that the functional synaptic alterations (<xref ref-type="fig" rid="fig4">Figure 4</xref>) observed in <italic>+/RC</italic> and <italic>+/GS</italic> mutant SPNs are not reflected in uniform changes in dendritic spine number or morphology.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Pathway-specific analysis of dendritic spine morphology in LRRK2 mutants.</title><p>(<bold>A</bold>) Example confocal maximum projection image of a <italic>+/RC;Adora2a-Cre</italic> iSPN expressing AAV8/Flex-GFP. Representative dendritic fragment with dendritic spines and the corresponding 3D Imaris generated filament. (<bold>B</bold>) Summary graph showing the dendritic spine density in pathway-identified SPNs across genotypes. Quantification of dendritic spine head width (<bold>C</bold>), and dendritic spine length (<bold>D</bold>) in d- and iSPNs. (<bold>E</bold>) Confocal maximum projection image and the corresponding 3D Imaris generated filament with classified dendritic spines. Red, stubby; green, mushroom; purple, filopodia. (<bold>F</bold>) <italic>Left</italic>, summary data showing the density of each dendritic spine category in dSPNs. <italic>Right</italic>, same as left, but for iSPNs.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical data represented as graphs in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig5-v2.tif"/></fig><media id="fig5video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-58997-fig5-video1.mp4"><label>Figure 5—video 1.</label><caption><title>3D Reconstruction of an identified <italic>+/RC;Adora2a-Cre</italic> (Drdr1-, iSPN) neuron transduced with a Cre-dependent AAV eGFP virus (AAV8/Flex-GFP) in neonatal pups.</title></caption></media></fig-group></sec><sec id="s2-5"><title>Enhanced single synapse glutamate uncaging-evoked currents in dSPNs of LRRK2 R1441C mutant SPNs</title><p>Our results indicate that the abundance of GluA1 subunits is selectively increased in dendritic spines of <italic>+/RC</italic> dSPNs, along with synaptic AMPAR presence and the prevalence of larger amplitude mEPSCs. This is consistent with a possibility that a specific fraction of <italic>+/RC</italic> excitatory synapses are functionally stronger. In order to evaluate the physiology of single dendritic spines in pathway-identified SPNs across three genotypes, we used two-photon dual laser glutamate uncaging and imaging, combined with whole-cell electrophysiology in voltage clamp mode (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). <italic>Drd2-eGFP</italic> mice were crossed into G2019S and R1441C KI lines, and maintained on a WT background for control groups. SPNs were filled with a cesium-based internal and Alexa 594 for imaging dendrites and dendritic spines at ~910 nm (<xref ref-type="fig" rid="fig6">Figure 6B–C</xref>); the presence or absence of GFP labeling was used to assign pathway identity. Uncaging evoked EPSCs (uEPSCs) were elicited using 0.5 ms long pulses of 725 nm laser light, directed near dendritic spines (~0.5–1 µm away), in order to drive focal uncaging of MNI-glutamate. Locations of peak responses, sampled for three sites near each dendritic spine, were chosen for data acquisition for every synapse. Recordings were carried out in the presence of blockers of GABAARs, NMDARs, muscarinic receptors, and sodium channels, for isolation of single synapse AMPAR responses. We found that single spine glutamate uEPSCs were increased in amplitude selectively in dSPNs of RC genotype mice (GFP-, <italic>+/RC</italic> 196% of control, GS, 102% of control; one-way ANOVA, p&lt;0.05, post hoc tests, as noted; n = 18–28 dendritic spines/group) (<xref ref-type="fig" rid="fig6">Figure 6D–F</xref>). For Drd2-eGFP<sup>+</sup> SPNs (iSPNs), no uEPSC amplitude differences were observed (GFP+, RC 70% of control, GS, 80% of control; one-way ANOVA, p=0.1682; n = 21–65 dendritic spines/group), suggesting a pathway-specific effect on single synapse function in the RC genotype.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>LRRK2 RC mutation increases glutamate uncaging-evoked currents in dSPNs.</title><p>(<bold>A</bold>) Schematic illustrating experimental design. (<bold>B</bold>) Example projection of a two-photon laser scanning microscopy stack showing an +/RC; GFP+ SPN (iSPN). Scale bar, 20 µm. (<bold>C</bold>) Close up images of representative dendrites from SPNs in the six genotype-pathway combinations, shown using inverse greyscale LUT. (<bold>D</bold>) Example single synapse AMPA-receptor-mediated currents, evoked by focal uncaging of MNI-glutamate. Scale bar, 20 pA and 100 ms. (<bold>E</bold>) Summary graph showing uncaging-evoked EPSCs (uEPSCs) for GFP-SPNs in controls, RC, and GS mutants. Asterisks reflect statistical significance for Tukey post-hoc comparisons after one-way ANOVA. (<bold>F</bold>) Same as E, but for GFP+ SPNs. (<bold>G</bold>) Summary schematic for the study, illustrating changes in synaptic content of glutamate receptors in LRRK2 mutations.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Numerical data of the graphs shown in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58997-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58997-fig6-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the present study, we characterized synaptic dysfunctions caused by mutant LRRK2 (RC and GS) in pathway-identified SPNs. To our knowledge, this is the first comparative approach focusing on more than one PD related LRRK2 mutation and employing both global and single synapse approaches for the study of LRRK2 driven striatal remodeling. By studying RC and GS KI mouse lines side by side, we were able to demonstrate that the two most common LRRK2 gain-of-function pathogenic mutations (<xref ref-type="bibr" rid="bib22">Hernandez et al., 2016</xref>) alter the function of SPN excitatory synapses in largely similar ways, with several potentially important differences. The observed changes were frequently stronger for the RC mutations, and more exaggerated in the direct pathway. For example, while whole cell electrophysiology recordings revealed decreases in the mESPCs frequency across both <italic>+/RC</italic> and <italic>+/GS</italic> mice, two-photon dual laser glutamate uncaging and imaging, combined with whole-cell electrophysiology, demonstrated larger amplitude in uEPSCs selectively for <italic>+/RC</italic> dSPNs. This observation paralleled higher synaptic GluA1 receptors levels in the same subtype <italic>+/RC</italic> SPNs (<xref ref-type="fig" rid="fig6">Figure 6G</xref>).</p><p>Based on the current knowledge, it remains unclear why the RC mutation is associated with somewhat more pronounced effects on sculpting striatal synapses. The GS mutation, which has been the main focus of the current literature, is found in the kinase domain of LRRK2, whereas the RC mutation is located in the GTPase domain of the protein (<xref ref-type="bibr" rid="bib36">Paisán-Ruiz et al., 2013</xref>), (<xref ref-type="bibr" rid="bib7">Cookson, 2012</xref>). It has been previously proposed that all pathogenic mutations lead to increased LRRK2 kinase activity, although the mechanism by which RC does this still remains unclear (<xref ref-type="bibr" rid="bib1">Alessi and Sammler, 2018</xref>; <xref ref-type="bibr" rid="bib34">Nguyen and Moore, 2017</xref>). Moreover, it is not known whether aberrant LRRK2 substrate phosphorylation is the predominant pathogenic mechanism in LRRK2 mediated striatal changes. Recent findings have revealed a subset of Rab family of proteins as the long awaited bona fide LRRK2 substrates (<xref ref-type="bibr" rid="bib49">Steger et al., 2016</xref>). Notably, the RC mutation, mainly in the context of heterologous cell lines, leads to higher increase in Rab phosphorylation compared to the GS mutation, which is localized to the kinase domain (<xref ref-type="bibr" rid="bib30">Liu et al., 2018</xref>), (<xref ref-type="bibr" rid="bib43">Purlyte et al., 2018</xref>). Similarly, the evidence of increased synaptic PKA activities was observed in <italic>+/RC</italic> and not <italic>+/GS</italic> striatal synaptic fractions. This increased PKA activity in the RC synapses is expected to positively correlate with elevations in dSPNs signaling (<xref ref-type="bibr" rid="bib68">Zhai et al., 2019</xref>). Specifically, phosphorylation of GluA1 at Ser 845 by PKA facilitates the targeting of the receptors to extrasynaptic membranes and their ‘priming’ for synaptic insertion and this results in elevated GluA1 synaptic incorporation (<xref ref-type="bibr" rid="bib11">Diering and Huganir, 2018</xref>). Indeed, our biochemical and SIM imaging data in RC mice support this notion. In contrast to dSPNs, PKA-driven signaling requirements for iSPNs are more complex, due to the involvement of adenosine. This molecule can be released by neurons or glia (<xref ref-type="bibr" rid="bib51">Surmeier et al., 2007</xref>), (<xref ref-type="bibr" rid="bib69">Zhang et al., 2019</xref>), complicating predictions for PKA involvement in mutant LRRK2 function in iSPNs.</p><p>Several prior reports demonstrate a LRRK2 mediated presynaptic regulation of glutamatergic transmission (<xref ref-type="bibr" rid="bib32">Matikainen-Ankney et al., 2016</xref>; <xref ref-type="bibr" rid="bib59">Volta et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Beccano-Kelly et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Piccoli et al., 2011</xref>), while emerging evidence emphasizes a postsynaptic role for LRRK2 (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Matikainen-Ankney et al., 2016</xref>). Our previous and current findings showed that LRRK2 contributes to glutamatergic synaptic functions by directing PKA signaling events in SPNs, leading to altered GluA1 synaptic incorporation in the striatum of RC mice (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>). Despite the elevated GluA1 levels in the synapses of <italic>+/RC</italic> dSPNs, there were no alterations in mean mEPSCs amplitude in these neurons. However, cumulative probability analysis demonstrated that the amplitude shifted toward larger values in the <italic>+/RC</italic> dSPNs, suggesting an inhomogeneity of synaptic function, where a fraction of synapses exhibit larger GluA1-dependent responses and single-synapse uncaging-evoked EPSCs. This scenario, on top of overall dampening of mEPSC frequency, is expected to bias mutant dSPN responses to be driven by a narrower set of glutamatergic inputs than is normally the case. Overtime, a small bias could be amplified through the recurrent circuitry of basal ganglia loops (<xref ref-type="bibr" rid="bib26">Kozorovitskiy et al., 2012</xref>). While there are some differences in the age of preparation and in recording conditions, our consistent finding of substantial miniature EPSC frequency decreases for both mutations in pathway-identified SPNs are in disagreement with prior recordings of spontaneous events in the GS mutant mice. One recent report showed elevations in spontaneous EPSCs events frequency in GS KI mice at 1–3 months (<xref ref-type="bibr" rid="bib59">Volta et al., 2017</xref>), while another reported changes in spontaneous but not miniature events with the GS mutation in pre-weaning mutants (<xref ref-type="bibr" rid="bib32">Matikainen-Ankney et al., 2016</xref>), although recordings were primarily performed in a mixed population of direct and indirect pathway SPNs, and neither study thoroughly compared the two mutations. Such differences in spontaneous event frequency point to a potential circuit-level compensatory mechanism that may be driven by disturbances in a subset of SPN excitatory synapses. Surprisingly, in the presence of clear functional and nano-architecture abnormalities, aggregate dendritic spine density and morphology, at least at the ages we evaluated, appeared normal. One possible explanation for this mismatch that requires further investigation is the possibility of higher occurrence of nonfunctional or differently functioning spines in LRRK2 mutant SPNs.</p><p>Given the critical role of LRRK2 in excitatory glutamatergic synapses (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Volta et al., 2017</xref>; <xref ref-type="bibr" rid="bib32">Matikainen-Ankney et al., 2016</xref>), a more nuanced understanding of LRRK2-mediated synaptic alterations should facilitate the search for more targeted PD therapies. Here, we focused primarily on interrogating cell type specific LRRK2-based responses. Why does this pathway specificity matter? It is well-established that dopamine loss causes pathway-specific morphological and functional changes in SPNs (<xref ref-type="bibr" rid="bib28">Kravitz et al., 2010</xref>; <xref ref-type="bibr" rid="bib13">Fieblinger et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Gertler et al., 2008</xref>). Moreover, dSPNs and iSPNs exhibit opposing PKA pathway signaling properties after dopamine receptor activation (<xref ref-type="bibr" rid="bib17">Gerfen and Surmeier, 2011</xref>; <xref ref-type="bibr" rid="bib51">Surmeier et al., 2007</xref>). Given the critical role of LRRK2 in synaptic PKA activities (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Tozzi et al., 2018b</xref>), these mutations are poised to have pathway specific effects and present distinct opportunities for pathway-targeted therapies. Over the past years, a number of transgenic mouse models was generated to study LRRK2 function (<xref ref-type="bibr" rid="bib60">Volta and Melrose, 2017</xref>; <xref ref-type="bibr" rid="bib66">Xiong et al., 2017</xref>); however, the results were found to be inconsistent across studies. Gene-targeted mutant LRRK2 KI mice represent the most physiologically relevant model to investigate LRRK2 mediated alterations and unravel disease mechanisms. Here, we attempt to synthesize and further the existing knowledge by employing a comparative approach focusing on two distinct mutations, combined with a powerful suite of techniques allowing for both global and single synapse study of LRRK2 SPNs.</p><p>The clinical phenotypes that define PD arise after a substantial loss of nigrostriatal dopamine signaling. Thus, the identification of pre-symptomatic dysfunctions offers a potential window of opportunity for the development of neuroprotective therapies in PD. Human asymptomatic LRRK2 mutation carriers represent an appropriate population to define these preclinical symptoms. Indeed, emerging evidence suggests that asymptomatic LRRK2 mutation carriers do show subtle motor and non-motor symptoms, including alterations of corticostriatal circuit organization, in comparison to asymptomatic non-carriers (<xref ref-type="bibr" rid="bib42">PPMI Investigators et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">LRRK2 Ashkenazi Jewish Consortium et al., 2015</xref>). Accordingly, cellular and synaptic dysfunctions in etiologically relevant LRRK2 mutant KI mice allow investigations of the early events that precede neuronal death and may be predictive of future dysfunction. Several studies have suggested a central role for LRRK2 in striatal SPNs (<xref ref-type="bibr" rid="bib59">Volta et al., 2017</xref>), (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Xenias, 2020</xref>). Here, we show that the presence of LRRK2 mutations can influence SPN function in a pathway-specific context, in the absence of dopamine neurodegeneration. Examining PD-relevant cellular functions in the absence of DA depletion represents a move away from the classical ways of studying PD in small rodent models, where basal ganglia cellular and network properties have been examined using several methods for dopamine depletion (<xref ref-type="bibr" rid="bib17">Gerfen and Surmeier, 2011</xref>; <xref ref-type="bibr" rid="bib29">Kreitzer and Malenka, 2008</xref>). While there is evidence that at first iSPNs show the primary structural and functional synaptic and dendritic changes in response to dopamine loss (<xref ref-type="bibr" rid="bib16">Gerfen, 2006</xref>; <xref ref-type="bibr" rid="bib18">Gertler et al., 2008</xref>; <xref ref-type="bibr" rid="bib9">Day et al., 2006</xref>; <xref ref-type="bibr" rid="bib58">Villalba et al., 2009</xref>), with time both SPNs types undergo substantial adaptations (<xref ref-type="bibr" rid="bib50">Suarez et al., 2018</xref>), (<xref ref-type="bibr" rid="bib14">Gagnon et al., 2017</xref>). Here, we find that some early changes in LRRK2 mutant dSPNs – including those observed at the single synapse level – are poised to contribute to the fragility of the system to lower levels of DA loss/variation. Because the well-described recurrent circuitry of the basal ganglia (<xref ref-type="bibr" rid="bib26">Kozorovitskiy et al., 2012</xref>), (<xref ref-type="bibr" rid="bib28">Kravitz et al., 2010</xref>; <xref ref-type="bibr" rid="bib35">Oldenburg and Sabatini, 2015</xref>) enables the output of direct and indirect pathways to feed back to regulate cortico-striatal glutamate release, minor synaptic defects in LRRK2 mutant SPNs could be amplified over time, contributing to the life-time risk of the disorder. The presence of early corticostriatal alterations in LRRK2 carriers (<xref ref-type="bibr" rid="bib31">LRRK2 Ashkenazi Jewish Consortium et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Vilas et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">the Barcelona LRRK2 Study Group et al., 2016</xref>), along with the evidence for finer scale synaptic dysfunctions reported in this study, open the possibilities for future personalized medicine approaches that take into account the specific LRRK2 mutation and emphasize protecting the health of striatal neurons prior to potential DA losses.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mouse strains and genotyping</title><p>All mouse related experiments followed the guidelines approved by the Northwestern University Animal Care and Use Committee. Young adult male and female mice (postnatal days 30–50) were used in this study. Approximately equal numbers of males and females were used for every experiment. All mice were group-housed, with standard feeding, light-dark cycle, and enrichment procedures. C57BL/6 (wild-type), <italic>RC</italic> (<xref ref-type="bibr" rid="bib54">Tong et al., 2009</xref>)<italic>, and GS</italic> (<xref ref-type="bibr" rid="bib67">Yue et al., 2015</xref>) heterozygous knock in mice were used for subcellular fractionation experiments. For electrophysiological and imaging approaches <italic>RC</italic> or <italic>GS</italic> mice were crossed with <italic>Drd1-dTomato</italic> and/or <italic>Drd2-eGFP</italic> mice. Heterozygotes <italic>for RC and GS</italic> allele and hemizygotes for <italic>Drd1-dTomato</italic> and/or <italic>Drd2-eGFP</italic> were used in all experiments. For dendritic spine analysis, hemizygous <italic>Drd1-Cre</italic>, and <italic>Adora2a-Cre</italic> mice crossed with RC and GS KI mice were used. All animals were backcrossed to C57BL/6 for several generations.</p></sec><sec id="s4-2"><title>Subcellular fractionation and western blot analysis</title><p>Subcellular fractionation of mouse striatum was performed as previously described (<xref ref-type="bibr" rid="bib4">Bermejo et al., 2014</xref>), (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>; <xref ref-type="fig" rid="fig1">Figure 1B</xref>). Specifically, mouse striata were dissected (three striata per experiment were pooled) and rapidly homogenized in four volumes of ice-cold Buffer A (0.32 M sucrose, 5 mM HEPES, pH7.4, 1 mM MgCl<sub>2</sub>, 0.5 mM CaCl<sub>2</sub>) supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo) using a Teflon homogenizer (12 strokes). Homogenized brain extract was centrifuged at 1400 <italic>g</italic> for 10 min. Supernatant (S1) was saved and pellet (P1) was homogenized in buffer A with a Teflon homogenizer (five strokes). After centrifugation at 700 <italic>g</italic> for 10 min, the supernatant (S1’) was pooled with S1. Pooled S1 and S1′ were centrifuged at 13,800 <italic>g</italic> for 10 min to the crude synaptosomal pellet (P2) and the supernatant (S2). P2 was resuspended in Buffer B (0.32 M sucrose, 6 mM Tris, pH 8.0) supplemented with protease and phosphatase inhibitors cocktail with Teflon homogenizer (five strokes) and was carefully loaded onto a discontinuous sucrose gradient (0.8 M/1 M/1.2 M sucrose solution in 6 mM Tris, pH 8.0) with a Pasteur pippete, followed by centrifugation in a swinging bucket rotor for 2 hr at 82,500 <italic>g</italic>. The synaptic plasma membrane fraction (SPM) in the interphase between 1 M and 1.2 M sucrose fractions was collected using a syringe and transferred to clean ultracentrifuge tubes. 6 mM Tris buffer was added to each sample to adjust the sucrose concentration from 1.2 M to 0.32 M and the samples were centrifuged in a swinging bucket rotor at 200,000 g for 30 min. The supernatant was removed and discarded and the SPM pellet was resuspended in 500 μl of 6 mM Tris/2 mM EDTA/0.5% Triton X-100 solution and rotated for 30 min at 4°C. In turn, the samples were centrifuged at 32,800 <italic>g</italic> for 20 min. The supernatant contains the Triton-soluble fraction (TSF), whereas the pellet represents the postsynaptic pellet (PSD).</p><p>S1, P2, presynaptic and PSD fractions were separated by 4–12% NuPage Bis-Tris PAGE (Invitrogen) and transferred to membranes using the iBlot nitrocellulose membrane Blotting system (Invitrogen) by following manufacture protocol. Primary antibodies specific for GluA1 (Cell Signaling Technology #13185), pGluA1 (Cell Signaling Technology #8084), phospho-PKA substrates (Cell Signaling Technologies #9624), phospho-Rab8A (Abcam, ab188574), total Rab 8A (Abcam, ab230260), phospho-Rab10 (Abcam ab230261) and total Rab10 (Cell Signaling Technologies #8127) as well as secondary anti-mouse and anti-rabbit (Thermo Fischer Scientific) Membranes were incubated with Immobilon ECL Ultra Western HRP Substrate (Millipore) for 3 min prior to image acquisition. Chemiluminescent blots were imaged with iBright CL1000 imaging system (Thermo Fisher Scientific). For quantitative analysis, images were analyzed using iBright Analysis Software (Thermo Fisher Scientific).</p></sec><sec id="s4-3"><title>Primary neuronal cultures</title><p>Primary corticostriatal co-cultures were prepared as described previously (<xref ref-type="bibr" rid="bib38">Parisiadou et al., 2014</xref>), (<xref ref-type="bibr" rid="bib53">Tian et al., 2010</xref>). In brief, striatal cultures were prepared from P0 pups of <italic>Drd1-Tomato</italic> or <italic>Drd2-eGFP</italic> mice crossed with mutant KI LRRK2 lines (<italic>G2019S</italic> and <italic>R1441C</italic>). Tissues were digested by papain (Worthington Biochemical Corporation) and the striatal and cortical cells were mixed at a ratio of 1:2. The neurons were placed on coveslips with plating medium (Medium I) containing Basal Eagle Medium (Sigma-Aldrich) supplemented with 1 x GlutaMAX (Gibco), 1 × B27 (Gibco), 1 x N-2 (Gibco), 1 x Antibiotic Antimycotic (Sigma-Aldrich), 5% horse serum (Gibco) and 5% FBS (Gibco) at a density of 4 × 10<sup>5</sup> for about one hour. After initial plating, medium was changed to Medium I without the horse serum and the FBS supplemented with 2.5 μM arabinosylcytosine (Sigma-Aldrich) (Medium II). Half of the medium was changed with fresh Medium II every 7 days; experiments were conducted 28–30 days after plating.</p></sec><sec id="s4-4"><title>SIM imaging and analysis</title><p>Multichannel SIM images were obtained with a Nikon Structured Illumination super-resolution microscope using a 100x, 1.4 NA objective as previously described (<xref ref-type="bibr" rid="bib48">Smith et al., 2014</xref>). The acquisition was set to 10 MHz, 16 bit depth with EM gain and no binning. Exposure was between 100 and 500 ms and the EM gain multiplier restrained below 1500. Conversion gain was held at 1x. Laser power was adjusted to keep LUTs within the first quarter of the scale. Single images were processed and analyzed using Nikon Elements software. Reconstruction parameters (Illumination Modulation Contrast, High Resolution Noise Suppression, and Out of Focus Blur Suppression) (0.94, 0.98, and 0.07) for GluA1/PSD95 and (1.2, 3.0, and 0.07) for GFP/tdTomato were kept consistent across all acquisitions and experiments. Single spine analyses were carried out on 72–95 spines across 9–12 neurons per genotype. Images of dendritic fragments were collected from secondary to tertiary dendrites across genotypes. All the spines on the fragments were analyzed. GFP/tdTomato signal (Thermo Fischer Scientific, #A10262/#M11217) was used to generate a mask to identify the spine shape, subsequent analysis were done with the nanodomains of GluA1 (NeuroMab #75327) and PSD95 (Thermo Fischer Scientific, #51–6900) within the mask. 3D reconstructions in a single plane used nine images captured with 2D SIM and reconstructed with 3D SIM utilizes 15 to increase xy and z resolution were generated by Nikon Element and the illumination modulation contrast was set automatically by the software. Nikon Elements software (general analysis) was used for quantification of colocalization of GluA1 and PSD95 proteins. The images were thresholded for each channel and kept constant across experiments. The regions of interest (puncta) were outlined, and total immunofluorescence number and binary area for each region per channel were measured automatically. Regions in one channel were overlayed on the other channel. The minimum distances between puncta (e.g. PSD95 to GluA1) were measured from surface to surface automatically by the software.</p></sec><sec id="s4-5"><title>Intracranial injections</title><p>Intracranial injections were performed as previously described (<xref ref-type="bibr" rid="bib26">Kozorovitskiy et al., 2012</xref>). Briefly, P4-5-day-old pups were placed into a stereotaxic frame under cryoanesthesia. 200 nl of AAV8/Flex-GFP virus (6.2*10<sup>12</sup> used at 1:3 dilution, UNC Vector Core, Chapel Hill, NC) were delivered into the dorsal striatum at a rate of 100 nl min<sup>−1</sup> using microprocessor-based controller, Micro4 (WPI). In order to ensure targeting of the dorsal striatum the needle was placed 1 mm anterior to midpoint between ear and eye, 1.5 mm from midline and 1.8 mm ventral to brain surface.</p></sec><sec id="s4-6"><title>Confocal microscopy and dendritic spine analysis</title><p>Confocal images of fixed 80-μm-thick brain sections of P30 pups injected with the AAV8/Flex-GFP virus were obtained with the Nikon A1R scope. Fluorescence projection images of dendrites and the corresponding spines were acquired with a 60x oil immersion objective (NA = 1.4) at 0.1 μm intervals with 1024 × 1024 pixel resolution. For each genotype, 2–4 segments per neuron, 9–14 neurons from 3 to 4 animals were used to generate z-stacks. Fragments between secondary to tertiary dendrites without overlap with other neurons or discontinuous were chosen for analysis. Dendritic spine density and morphology was performed using Imaris 9.21 software (Bitplane, Concord, USA). Images of dendritic fragments were collected from secondary to tertiary dendrites, for tracing of the dendritic fragments the autopath mode of the filament tracer and default settings were selected. The following settings were used for spine detection: 0.5 μm minimal head size, 1.8 μm maximum length, seed point threshold approx. 10, no branched spines were allowed. Spine detection was manually corrected if necessary. Classification of spines into stubby, mushroom-like and filopodia was performed using the Imaris XTension classify spines with following definitions: stubby: spine length &lt;0.75 μm; mushroom: spine length &lt;3.5 μm, spine head width &gt;0.35 μm and spine head width &gt;spine neck width; filopodia: when it did not fit the criteria mentioned above (<xref ref-type="bibr" rid="bib46">Schier et al., 2017</xref>).</p></sec><sec id="s4-7"><title>Electrophysiological recordings</title><p>Two hundred and fifty µm thick acute coronal brain slices were prepared as described previously (<xref ref-type="bibr" rid="bib27">Kozorovitskiy et al., 2015</xref>), (<xref ref-type="bibr" rid="bib63">Xiao et al., 2017</xref>) and incubated in artificial cerebral spinal fluid (ACSF) containing (in mM) 127 NaCl, 2.5 KCl, 25 NaHCO<sub>3</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 2.0 CaCl<sub>2</sub>, 1.0 MgCl<sub>2</sub>, and 25 glucose (osmolarity ~310 mOsm/L). Slices were recovered at 34°C for 15 min, followed by 30 min at RT, and transferred to a recording chamber perfused with oxygenated ACSF at a flow rate of 2–3 mL/min. Whole-cell recordings were obtained from dorsolateral striatal neurons visualized under infrared Dodt or DIC contrast video microscopy using patch pipettes of ~4–6 MΩ resistance. Drd2 BAC GFP signal visualized under epifluorescence was used to target iSPNs, while Drd2 GFP-negative neurons with spiny dendrites and electrophysiological properties of SPNs (holding current, input resistance) were considered dSPNs (<xref ref-type="bibr" rid="bib14">Gagnon et al., 2017</xref>), (<xref ref-type="bibr" rid="bib20">Gittis et al., 2010</xref>). Both fluorescent and non-fluorescent neurons were targeted for recording. Internal solution consisted of (in mM): 120 CsMeSO<sub>4</sub>, 15 CsCl, 10 HEPES, 2 QX-314 Chloride, 2 Mg-ATP, 0.3 Na-GTP, 1 EGTA (pH ~7.2,~295 mOsm). Morphology was confirmed using 20 µM Alexa 594 in the recording pipette. Recordings were made using a Multiclamp 700B amplifier (Molecular Devices). Data were sampled at 10 kHz and filtered at 4 kHz, acquired in MATLAB (MathWorks). Series resistance, measured with a 5 mV hyperpolarizing pulse in voltage clamp, averaged under 20 MΩ and was left uncompensated. Miniature EPSCs were recorded from voltage clamped SPNs held at −70 mV in the absence of stimulation. Over 2 min of recording per neuron was used for analyses. For recordings of miniature EPSCs, 50 µM gabazine, 10 µM scopolamine, 10 µM CPP, and 1 µM TTX were added to the ACSF.</p></sec><sec id="s4-8"><title>Two-photon imaging and uncaging</title><p>Two-photon laser-scanning microscopy and two-photon laser photoactivation were accomplished on a modified Scientifica microscope with a 60X (1.0 NA) objective. Two mode-locked Ti:Sapphire lasers (Mai-Tai eHP Deep See and Mai-Tai eHP; Spectra Physics) were separately tuned, with beam power controlled by independent Pockels cells (ConOptics). The beams were separately shuttered, recombined using a polarization-sensitive beam-splitting cube (Thorlabs), and guided into the same galvanometer scanhead (Cambridge). The Mai Tai eHP Deep See was tuned to ~910 nm for excitation of genetically encoded GFP and Alexa 594, and the Mai Tai eHP was tuned to 725 nm for photoactivation of recirculated caged MNI-L-glutamate (2 mM, Tocris) (<xref ref-type="bibr" rid="bib64">Xiao et al., 2018</xref>; <xref ref-type="bibr" rid="bib2">Banala et al., 2018</xref>). Neurons in the dorsolateral striatum were targeted for recording, as for other electrophysiology assays, with secondary and tertiary dendrites targeted for uncaging. All 2P uncaging voltage clamp recordings were made at a holding potential of −70 mV. Internal solution contained (in mM) 115 K-gluconate, 20 KCl, 4 MgCl<sub>2</sub>, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP, 7 phosphocreatine, 0.1 EGTA, (pH 7.2, 290 mOSm). Alexa Fluor 594 (10–20 μM) was added to the internal solution to visualize cell morphology for uncaging/imaging with physiology experiments. Uncaging evoked EPSCs were elicited by 0.5 ms pulses of 725 nm laser light (~20 mW at the focal plane). Up to three locations in a single field of view were stimulated (1 s apart) in a single sweep. Stimulation of a single location occurred with a minimum 10 s ISI. A spot diameter of ≤0.8 μm, based on measurements of 0.5 μm beads (17152–10; Polysciences Inc) was used for all two-photon laser flash photolysis experiments. Two GaAsP photosensors (Hamamatsu, H7422) with 520/28 nm band pass filters (Semrock), mounted above and below the sample, were used for imaging fluorescence signals. A modified version of ScanImage was used for data acquisition (<xref ref-type="bibr" rid="bib41">Pologruto et al., 2003</xref>), (<xref ref-type="bibr" rid="bib27">Kozorovitskiy et al., 2015</xref>).</p></sec><sec id="s4-9"><title>Statistical analyses</title><p>Group statistical analyses were done using GraphPad Prism seven software (GraphPad, LaJolla, CA). For n sizes, both the number of trials recorded and the number of animals are provided. All data are expressed as mean + SEM, or individual plots. For two-group comparisons, statistical significance was determined by two-tailed Student’s t-tests. For multiple group comparisons, one-way analysis of variance (ANOVA) tests were used for normally distributed data, followed by post-hoc analyses. For non-normally distributed data, non-parametric tests for the appropriate group numbers were used, such as the Mann-Whitney test. For the analysis of mEPSC amplitude distributions, data were fit with a gamma distribution, a non-negative asymmetrical distribution, because the mEPSC amplitude data were not normally or lognormally distributed but displayed appropriate skew and kurtosis to match the gamma distribution. Generalized linear modeling (GLM) with a gamma family distribution was used to estimate and compare mEPSC amplitudes, with Bonferroni corrections for multiple posthoc comparisons. All mEPSC distribution analyses were done in R, using fitdistrplus library and the emmeans package. Spearman correlation was used to detect correlation between two groups of data. p&lt;0.05 was considered statistically significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by Michael J Fox Foundation for Parkinson’s Research (LP), NIH R01 NS097901 (LP), NINDS R01 NS107539 (YK), Rita Allen Foundation Scholar Award (YK), Searle Scholar Award (YK), and Beckman Young Investigator Award (YK). NB was supported by NINDS F32 NS103243 and VD by a predoctoral award from the American Heart Association (19PRE34380056). SIM imaging was performed at the Center for Advanced Microcopy, Northwestern University, supported by the NIH 1S10OD016342-01 and NCI CCSG P30 CA060553. The authors are grateful to Lindsey Butler for mouse colony management. We also thank Dr. Heather Melrose for providing the LRRK2 G2019S knock-in mice.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All mouse experiments were approved by Northwestern University Animal Care and Use Committee (Approved protocol numbers IS000035451, IS00000838, and 00009022).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-58997-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alessi</surname> <given-names>DR</given-names></name><name><surname>Sammler</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LRRK2 kinase in Parkinson's disease</article-title><source>Science</source><volume>360</volume><fpage>36</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1126/science.aar5683</pub-id><pub-id pub-id-type="pmid">29622645</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banala</surname> <given-names>S</given-names></name><name><surname>Arvin</surname> <given-names>MC</given-names></name><name><surname>Bannon</surname> <given-names>NM</given-names></name><name><surname>Jin</surname> <given-names>XT</given-names></name><name><surname>Macklin</surname> <given-names>JJ</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>C</given-names></name><name><surname>Zhao</surname> <given-names>G</given-names></name><name><surname>Marshall</surname> <given-names>JJ</given-names></name><name><surname>Gee</surname> <given-names>KR</given-names></name><name><surname>Wokosin</surname> <given-names>DL</given-names></name><name><surname>Kim</surname> <given-names>VJ</given-names></name><name><surname>McIntosh</surname> <given-names>JM</given-names></name><name><surname>Contractor</surname> <given-names>A</given-names></name><name><surname>Lester</surname> <given-names>HA</given-names></name><name><surname>Kozorovitskiy</surname> <given-names>Y</given-names></name><name><surname>Drenan</surname> <given-names>RM</given-names></name><name><surname>Lavis</surname> <given-names>LD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Photoactivatable drugs for nicotinic optopharmacology</article-title><source>Nature Methods</source><volume>15</volume><fpage>347</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4637</pub-id><pub-id pub-id-type="pmid">29578537</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beccano-Kelly</surname> <given-names>DA</given-names></name><name><surname>Volta</surname> <given-names>M</given-names></name><name><surname>Munsie</surname> <given-names>LN</given-names></name><name><surname>Paschall</surname> <given-names>SA</given-names></name><name><surname>Tatarnikov</surname> <given-names>I</given-names></name><name><surname>Co</surname> <given-names>K</given-names></name><name><surname>Chou</surname> <given-names>P</given-names></name><name><surname>Cao</surname> <given-names>LP</given-names></name><name><surname>Bergeron</surname> <given-names>S</given-names></name><name><surname>Mitchell</surname> <given-names>E</given-names></name><name><surname>Han</surname> <given-names>H</given-names></name><name><surname>Melrose</surname> <given-names>HL</given-names></name><name><surname>Tapia</surname> <given-names>L</given-names></name><name><surname>Raymond</surname> <given-names>LA</given-names></name><name><surname>Farrer</surname> <given-names>MJ</given-names></name><name><surname>Milnerwood</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>1336</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu543</pub-id><pub-id pub-id-type="pmid">25343991</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bermejo</surname> <given-names>MK</given-names></name><name><surname>Milenkovic</surname> <given-names>M</given-names></name><name><surname>Salahpour</surname> <given-names>A</given-names></name><name><surname>Ramsey</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Preparation of synaptic plasma membrane and postsynaptic density proteins using a discontinuous sucrose gradient</article-title><source>Journal of Visualized Experiments</source><volume>3</volume><elocation-id>e51896</elocation-id><pub-id pub-id-type="doi">10.3791/51896</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonet-Ponce</surname> <given-names>L</given-names></name><name><surname>Cookson</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of rab GTPases in the pathobiology of parkinson' disease</article-title><source>Current Opinion in Cell Biology</source><volume>59</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2019.03.009</pub-id><pub-id pub-id-type="pmid">31054512</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cookson</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</article-title><source>Nature Reviews Neuroscience</source><volume>11</volume><fpage>791</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/nrn2935</pub-id><pub-id pub-id-type="pmid">21088684</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cookson</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cellular effects of LRRK2 mutations</article-title><source>Biochemical Society Transactions</source><volume>40</volume><fpage>1070</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1042/BST20120165</pub-id><pub-id pub-id-type="pmid">22988867</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crosby</surname> <given-names>KC</given-names></name><name><surname>Gookin</surname> <given-names>SE</given-names></name><name><surname>Garcia</surname> <given-names>JD</given-names></name><name><surname>Hahm</surname> <given-names>KM</given-names></name><name><surname>Dell'Acqua</surname> <given-names>ML</given-names></name><name><surname>Smith</surname> <given-names>KR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nanoscale subsynaptic domains underlie the organization of the inhibitory synapse</article-title><source>Cell Reports</source><volume>26</volume><fpage>3284</fpage><lpage>3297</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.02.070</pub-id><pub-id pub-id-type="pmid">30893601</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Ding</surname> <given-names>J</given-names></name><name><surname>An</surname> <given-names>X</given-names></name><name><surname>Ingham</surname> <given-names>CA</given-names></name><name><surname>Shering</surname> <given-names>AF</given-names></name><name><surname>Wokosin</surname> <given-names>D</given-names></name><name><surname>Ilijic</surname> <given-names>E</given-names></name><name><surname>Sun</surname> <given-names>Z</given-names></name><name><surname>Sampson</surname> <given-names>AR</given-names></name><name><surname>Mugnaini</surname> <given-names>E</given-names></name><name><surname>Deutch</surname> <given-names>AY</given-names></name><name><surname>Sesack</surname> <given-names>SR</given-names></name><name><surname>Arbuthnott</surname> <given-names>GW</given-names></name><name><surname>Surmeier</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Selective elimination of glutamatergic synapses on striatopallidal neurons in parkinson disease models</article-title><source>Nature Neuroscience</source><volume>9</volume><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/nn1632</pub-id><pub-id pub-id-type="pmid">16415865</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Maio</surname> <given-names>R</given-names></name><name><surname>Hoffman</surname> <given-names>EK</given-names></name><name><surname>Rocha</surname> <given-names>EM</given-names></name><name><surname>Keeney</surname> <given-names>MT</given-names></name><name><surname>Sanders</surname> <given-names>LH</given-names></name><name><surname>De Miranda</surname> <given-names>BR</given-names></name><name><surname>Zharikov</surname> <given-names>A</given-names></name><name><surname>Van Laar</surname> <given-names>A</given-names></name><name><surname>Stepan</surname> <given-names>AF</given-names></name><name><surname>Lanz</surname> <given-names>TA</given-names></name><name><surname>Kofler</surname> <given-names>JK</given-names></name><name><surname>Burton</surname> <given-names>EA</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name><name><surname>Hastings</surname> <given-names>TG</given-names></name><name><surname>Greenamyre</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LRRK2 activation in idiopathic Parkinson's disease</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaar5429</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aar5429</pub-id><pub-id pub-id-type="pmid">30045977</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diering</surname> <given-names>GH</given-names></name><name><surname>Huganir</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The AMPA receptor code of synaptic plasticity</article-title><source>Neuron</source><volume>100</volume><fpage>314</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.10.018</pub-id><pub-id pub-id-type="pmid">30359599</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteves</surname> <given-names>AR</given-names></name><name><surname>Swerdlow</surname> <given-names>RH</given-names></name><name><surname>Cardoso</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis</article-title><source>Experimental Neurology</source><volume>261</volume><fpage>206</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2014.05.025</pub-id><pub-id pub-id-type="pmid">24907399</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fieblinger</surname> <given-names>T</given-names></name><name><surname>Graves</surname> <given-names>SM</given-names></name><name><surname>Sebel</surname> <given-names>LE</given-names></name><name><surname>Alcacer</surname> <given-names>C</given-names></name><name><surname>Plotkin</surname> <given-names>JL</given-names></name><name><surname>Gertler</surname> <given-names>TS</given-names></name><name><surname>Chan</surname> <given-names>CS</given-names></name><name><surname>Heiman</surname> <given-names>M</given-names></name><name><surname>Greengard</surname> <given-names>P</given-names></name><name><surname>Cenci</surname> <given-names>MA</given-names></name><name><surname>Surmeier</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5316</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6316</pub-id><pub-id pub-id-type="pmid">25360704</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname> <given-names>D</given-names></name><name><surname>Petryszyn</surname> <given-names>S</given-names></name><name><surname>Sanchez</surname> <given-names>MG</given-names></name><name><surname>Bories</surname> <given-names>C</given-names></name><name><surname>Beaulieu</surname> <given-names>JM</given-names></name><name><surname>De Koninck</surname> <given-names>Y</given-names></name><name><surname>Parent</surname> <given-names>A</given-names></name><name><surname>Parent</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Striatal neurons expressing D<sub>1</sub> and D<sub>2</sub> Receptors are Morphologically Distinct and Differently Affected by Dopamine Denervation in Mice</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>41432</elocation-id><pub-id pub-id-type="doi">10.1038/srep41432</pub-id><pub-id pub-id-type="pmid">28128287</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>R</given-names></name><name><surname>Piguel</surname> <given-names>NH</given-names></name><name><surname>Melendez-Zaidi</surname> <given-names>AE</given-names></name><name><surname>Martin-de-Saavedra</surname> <given-names>MD</given-names></name><name><surname>Yoon</surname> <given-names>S</given-names></name><name><surname>Forrest</surname> <given-names>MP</given-names></name><name><surname>Myczek</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Russell</surname> <given-names>TA</given-names></name><name><surname>Csernansky</surname> <given-names>JG</given-names></name><name><surname>Surmeier</surname> <given-names>DJ</given-names></name><name><surname>Penzes</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CNTNAP2 stabilizes interneuron dendritic arbors through CASK</article-title><source>Molecular Psychiatry</source><volume>23</volume><fpage>1832</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0027-3</pub-id><pub-id pub-id-type="pmid">29610457</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerfen</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Indirect-pathway neurons lose their spines in parkinson disease</article-title><source>Nature Neuroscience</source><volume>9</volume><fpage>157</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/nn0206-157</pub-id><pub-id pub-id-type="pmid">16439979</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerfen</surname> <given-names>CR</given-names></name><name><surname>Surmeier</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Modulation of striatal projection systems by dopamine</article-title><source>Annual Review of Neuroscience</source><volume>34</volume><fpage>441</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113641</pub-id><pub-id pub-id-type="pmid">21469956</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gertler</surname> <given-names>TS</given-names></name><name><surname>Chan</surname> <given-names>CS</given-names></name><name><surname>Surmeier</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dichotomous anatomical properties of adult striatal medium spiny neurons</article-title><source>Journal of Neuroscience</source><volume>28</volume><fpage>10814</fpage><lpage>10824</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2660-08.2008</pub-id><pub-id pub-id-type="pmid">18945889</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giesert</surname> <given-names>F</given-names></name><name><surname>Hofmann</surname> <given-names>A</given-names></name><name><surname>Bürger</surname> <given-names>A</given-names></name><name><surname>Zerle</surname> <given-names>J</given-names></name><name><surname>Kloos</surname> <given-names>K</given-names></name><name><surname>Hafen</surname> <given-names>U</given-names></name><name><surname>Ernst</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Vogt-Weisenhorn</surname> <given-names>DM</given-names></name><name><surname>Wurst</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e63778</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0063778</pub-id><pub-id pub-id-type="pmid">23675505</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gittis</surname> <given-names>AH</given-names></name><name><surname>Nelson</surname> <given-names>AB</given-names></name><name><surname>Thwin</surname> <given-names>MT</given-names></name><name><surname>Palop</surname> <given-names>JJ</given-names></name><name><surname>Kreitzer</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Distinct roles of GABAergic interneurons in the regulation of striatal output pathways</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>2223</fpage><lpage>2234</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4870-09.2010</pub-id><pub-id pub-id-type="pmid">20147549</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haugarvoll</surname> <given-names>K</given-names></name><name><surname>Rademakers</surname> <given-names>R</given-names></name><name><surname>Kachergus</surname> <given-names>JM</given-names></name><name><surname>Nuytemans</surname> <given-names>K</given-names></name><name><surname>Ross</surname> <given-names>OA</given-names></name><name><surname>Gibson</surname> <given-names>JM</given-names></name><name><surname>Tan</surname> <given-names>EK</given-names></name><name><surname>Gaig</surname> <given-names>C</given-names></name><name><surname>Tolosa</surname> <given-names>E</given-names></name><name><surname>Goldwurm</surname> <given-names>S</given-names></name><name><surname>Guidi</surname> <given-names>M</given-names></name><name><surname>Riboldazzi</surname> <given-names>G</given-names></name><name><surname>Brown</surname> <given-names>L</given-names></name><name><surname>Walter</surname> <given-names>U</given-names></name><name><surname>Benecke</surname> <given-names>R</given-names></name><name><surname>Berg</surname> <given-names>D</given-names></name><name><surname>Gasser</surname> <given-names>T</given-names></name><name><surname>Theuns</surname> <given-names>J</given-names></name><name><surname>Pals</surname> <given-names>P</given-names></name><name><surname>Cras</surname> <given-names>P</given-names></name><name><surname>De Deyn</surname> <given-names>PP</given-names></name><name><surname>Engelborghs</surname> <given-names>S</given-names></name><name><surname>Pickut</surname> <given-names>B</given-names></name><name><surname>Uitti</surname> <given-names>RJ</given-names></name><name><surname>Foroud</surname> <given-names>T</given-names></name><name><surname>Nichols</surname> <given-names>WC</given-names></name><name><surname>Hagenah</surname> <given-names>J</given-names></name><name><surname>Klein</surname> <given-names>C</given-names></name><name><surname>Samii</surname> <given-names>A</given-names></name><name><surname>Zabetian</surname> <given-names>CP</given-names></name><name><surname>Bonifati</surname> <given-names>V</given-names></name><name><surname>Van Broeckhoven</surname> <given-names>C</given-names></name><name><surname>Farrer</surname> <given-names>MJ</given-names></name><name><surname>Wszolek</surname> <given-names>ZK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lrrk2 R1441C parkinsonism is clinically similar to sporadic parkinson disease</article-title><source>Neurology</source><volume>70</volume><fpage>1456</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000304044.22253.03</pub-id><pub-id pub-id-type="pmid">18337586</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname> <given-names>DG</given-names></name><name><surname>Reed</surname> <given-names>X</given-names></name><name><surname>Singleton</surname> <given-names>AB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genetics in parkinson disease: mendelian versus non-Mendelian inheritance</article-title><source>Journal of Neurochemistry</source><volume>139 Suppl 1</volume><fpage>59</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/jnc.13593</pub-id><pub-id pub-id-type="pmid">27090875</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Huntley</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>LRRK2 mutation alters behavioral, synaptic and non-synaptic adaptations to acute social stress</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.02.25.965194</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Italian Parkinson's Genetics Network</collab><name><surname>Di Fonzo</surname> <given-names>A</given-names></name><name><surname>Tassorelli</surname> <given-names>C</given-names></name><name><surname>De Mari</surname> <given-names>M</given-names></name><name><surname>Chien</surname> <given-names>HF</given-names></name><name><surname>Ferreira</surname> <given-names>J</given-names></name><name><surname>Rohé</surname> <given-names>CF</given-names></name><name><surname>Riboldazzi</surname> <given-names>G</given-names></name><name><surname>Antonini</surname> <given-names>A</given-names></name><name><surname>Albani</surname> <given-names>G</given-names></name><name><surname>Mauro</surname> <given-names>A</given-names></name><name><surname>Marconi</surname> <given-names>R</given-names></name><name><surname>Abbruzzese</surname> <given-names>G</given-names></name><name><surname>Lopiano</surname> <given-names>L</given-names></name><name><surname>Fincati</surname> <given-names>E</given-names></name><name><surname>Guidi</surname> <given-names>M</given-names></name><name><surname>Marini</surname> <given-names>P</given-names></name><name><surname>Stocchi</surname> <given-names>F</given-names></name><name><surname>Onofrj</surname> <given-names>M</given-names></name><name><surname>Toni</surname> <given-names>V</given-names></name><name><surname>Tinazzi</surname> <given-names>M</given-names></name><name><surname>Fabbrini</surname> <given-names>G</given-names></name><name><surname>Lamberti</surname> <given-names>P</given-names></name><name><surname>Vanacore</surname> <given-names>N</given-names></name><name><surname>Meco</surname> <given-names>G</given-names></name><name><surname>Leitner</surname> <given-names>P</given-names></name><name><surname>Uitti</surname> <given-names>RJ</given-names></name><name><surname>Wszolek</surname> <given-names>ZK</given-names></name><name><surname>Gasser</surname> <given-names>T</given-names></name><name><surname>Simons</surname> <given-names>EJ</given-names></name><name><surname>Breedveld</surname> <given-names>GJ</given-names></name><name><surname>Goldwurm</surname> <given-names>S</given-names></name><name><surname>Pezzoli</surname> <given-names>G</given-names></name><name><surname>Sampaio</surname> <given-names>C</given-names></name><name><surname>Barbosa</surname> <given-names>E</given-names></name><name><surname>Martignoni</surname> <given-names>E</given-names></name><name><surname>Oostra</surname> <given-names>BA</given-names></name><name><surname>Bonifati</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease</article-title><source>European Journal of Human Genetics</source><volume>14</volume><fpage>322</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201539</pub-id><pub-id pub-id-type="pmid">16333314</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluss</surname> <given-names>JH</given-names></name><name><surname>Mamais</surname> <given-names>A</given-names></name><name><surname>Cookson</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>LRRK2 links genetic and sporadic parkinson's disease</article-title><source>Biochemical Society Transactions</source><volume>47</volume><fpage>651</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1042/BST20180462</pub-id><pub-id pub-id-type="pmid">30837320</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozorovitskiy</surname> <given-names>Y</given-names></name><name><surname>Saunders</surname> <given-names>A</given-names></name><name><surname>Johnson</surname> <given-names>CA</given-names></name><name><surname>Lowell</surname> <given-names>BB</given-names></name><name><surname>Sabatini</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Recurrent network activity drives striatal synaptogenesis</article-title><source>Nature</source><volume>485</volume><fpage>646</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/nature11052</pub-id><pub-id pub-id-type="pmid">22660328</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozorovitskiy</surname> <given-names>Y</given-names></name><name><surname>Peixoto</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Saunders</surname> <given-names>A</given-names></name><name><surname>Sabatini</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuromodulation of excitatory synaptogenesis in striatal development</article-title><source>eLife</source><volume>4</volume><elocation-id>e10111</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10111</pub-id><pub-id pub-id-type="pmid">26551563</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kravitz</surname> <given-names>AV</given-names></name><name><surname>Freeze</surname> <given-names>BS</given-names></name><name><surname>Parker</surname> <given-names>PR</given-names></name><name><surname>Kay</surname> <given-names>K</given-names></name><name><surname>Thwin</surname> <given-names>MT</given-names></name><name><surname>Deisseroth</surname> <given-names>K</given-names></name><name><surname>Kreitzer</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry</article-title><source>Nature</source><volume>466</volume><fpage>622</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1038/nature09159</pub-id><pub-id pub-id-type="pmid">20613723</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreitzer</surname> <given-names>AC</given-names></name><name><surname>Malenka</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Striatal plasticity and basal ganglia circuit function</article-title><source>Neuron</source><volume>60</volume><fpage>543</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2008.11.005</pub-id><pub-id pub-id-type="pmid">19038213</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Bryant</surname> <given-names>N</given-names></name><name><surname>Kumaran</surname> <given-names>R</given-names></name><name><surname>Beilina</surname> <given-names>A</given-names></name><name><surname>Abeliovich</surname> <given-names>A</given-names></name><name><surname>Cookson</surname> <given-names>MR</given-names></name><name><surname>West</surname> <given-names>AB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LRRK2 phosphorylates membrane-bound rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network</article-title><source>Human Molecular Genetics</source><volume>27</volume><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx410</pub-id><pub-id pub-id-type="pmid">29177506</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>LRRK2 Ashkenazi Jewish Consortium</collab><name><surname>Helmich</surname> <given-names>RC</given-names></name><name><surname>Thaler</surname> <given-names>A</given-names></name><name><surname>van Nuenen</surname> <given-names>BF</given-names></name><name><surname>Gurevich</surname> <given-names>T</given-names></name><name><surname>Mirelman</surname> <given-names>A</given-names></name><name><surname>Marder</surname> <given-names>KS</given-names></name><name><surname>Bressman</surname> <given-names>S</given-names></name><name><surname>Orr-Urtreger</surname> <given-names>A</given-names></name><name><surname>Giladi</surname> <given-names>N</given-names></name><name><surname>Bloem</surname> <given-names>BR</given-names></name><name><surname>Toni</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers</article-title><source>Neurology</source><volume>84</volume><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001189</pub-id><pub-id pub-id-type="pmid">25540317</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matikainen-Ankney</surname> <given-names>BA</given-names></name><name><surname>Kezunovic</surname> <given-names>N</given-names></name><name><surname>Mesias</surname> <given-names>RE</given-names></name><name><surname>Tian</surname> <given-names>Y</given-names></name><name><surname>Williams</surname> <given-names>FM</given-names></name><name><surname>Huntley</surname> <given-names>GW</given-names></name><name><surname>Benson</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Altered development of synapse structure and function in striatum caused by parkinson's Disease-Linked LRRK2-G2019S Mutation</article-title><source>Journal of Neuroscience</source><volume>36</volume><fpage>7128</fpage><lpage>7141</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3314-15.2016</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matikainen-Ankney</surname> <given-names>BA</given-names></name><name><surname>Kezunovic</surname> <given-names>N</given-names></name><name><surname>Menard</surname> <given-names>C</given-names></name><name><surname>Flanigan</surname> <given-names>ME</given-names></name><name><surname>Zhong</surname> <given-names>Y</given-names></name><name><surname>Russo</surname> <given-names>SJ</given-names></name><name><surname>Benson</surname> <given-names>DL</given-names></name><name><surname>Huntley</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood</article-title><source>The Journal of Neuroscience</source><volume>38</volume><fpage>9700</fpage><lpage>9711</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1457-18.2018</pub-id><pub-id pub-id-type="pmid">30249796</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>AP</given-names></name><name><surname>Moore</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Understanding the GTPase activity of LRRK2: regulation, function, and neurotoxicity</article-title><source>Advances in Neurobiology</source><volume>14</volume><fpage>71</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-49969-7_4</pub-id><pub-id pub-id-type="pmid">28353279</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldenburg</surname> <given-names>IA</given-names></name><name><surname>Sabatini</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Antagonistic but not symmetric regulation of primary motor cortex by basal ganglia direct and indirect pathways</article-title><source>Neuron</source><volume>86</volume><fpage>1174</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.05.008</pub-id><pub-id pub-id-type="pmid">26050037</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisán-Ruiz</surname> <given-names>C</given-names></name><name><surname>Lewis</surname> <given-names>PA</given-names></name><name><surname>Singleton</surname> <given-names>AB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>LRRK2: cause, risk, and mechanism</article-title><source>Journal of Parkinson's Disease</source><volume>3</volume><fpage>85</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.3233/JPD-130192</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname> <given-names>PY</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Powell</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Wicinski</surname> <given-names>B</given-names></name><name><surname>Hof</surname> <given-names>P</given-names></name><name><surname>Ryan</surname> <given-names>TA</given-names></name><name><surname>Yue</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons</article-title><source>The Journal of Neuroscience</source><volume>37</volume><fpage>11366</fpage><lpage>11376</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0964-17.2017</pub-id><pub-id pub-id-type="pmid">29054882</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisiadou</surname> <given-names>L</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Sgobio</surname> <given-names>C</given-names></name><name><surname>Xie</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Gu</surname> <given-names>XL</given-names></name><name><surname>Lin</surname> <given-names>X</given-names></name><name><surname>Crowley</surname> <given-names>NA</given-names></name><name><surname>Lovinger</surname> <given-names>DM</given-names></name><name><surname>Cai</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity</article-title><source>Nature Neuroscience</source><volume>17</volume><fpage>367</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1038/nn.3636</pub-id><pub-id pub-id-type="pmid">24464040</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>MJ</given-names></name><name><surname>Cheng</surname> <given-names>D</given-names></name><name><surname>Duong</surname> <given-names>DM</given-names></name><name><surname>Gygi</surname> <given-names>SP</given-names></name><name><surname>Sheng</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Semiquantitative proteomic analysis of rat forebrain postsynaptic density fractions by mass spectrometry</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>21003</fpage><lpage>21011</lpage><pub-id pub-id-type="doi">10.1074/jbc.M400103200</pub-id><pub-id pub-id-type="pmid">15020595</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccoli</surname> <given-names>G</given-names></name><name><surname>Condliffe</surname> <given-names>SB</given-names></name><name><surname>Bauer</surname> <given-names>M</given-names></name><name><surname>Giesert</surname> <given-names>F</given-names></name><name><surname>Boldt</surname> <given-names>K</given-names></name><name><surname>De Astis</surname> <given-names>S</given-names></name><name><surname>Meixner</surname> <given-names>A</given-names></name><name><surname>Sarioglu</surname> <given-names>H</given-names></name><name><surname>Vogt-Weisenhorn</surname> <given-names>DM</given-names></name><name><surname>Wurst</surname> <given-names>W</given-names></name><name><surname>Gloeckner</surname> <given-names>CJ</given-names></name><name><surname>Matteoli</surname> <given-names>M</given-names></name><name><surname>Sala</surname> <given-names>C</given-names></name><name><surname>Ueffing</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>2225</fpage><lpage>2237</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3730-10.2011</pub-id><pub-id pub-id-type="pmid">21307259</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pologruto</surname> <given-names>TA</given-names></name><name><surname>Sabatini</surname> <given-names>BL</given-names></name><name><surname>Svoboda</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>ScanImage: flexible software for operating laser scanning microscopes</article-title><source>BioMedical Engineering OnLine</source><volume>2</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1475-925X-2-13</pub-id><pub-id pub-id-type="pmid">12801419</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>PPMI Investigators</collab><name><surname>Simuni</surname> <given-names>T</given-names></name><name><surname>Uribe</surname> <given-names>L</given-names></name><name><surname>Cho</surname> <given-names>HR</given-names></name><name><surname>Caspell-Garcia</surname> <given-names>C</given-names></name><name><surname>Coffey</surname> <given-names>CS</given-names></name><name><surname>Siderowf</surname> <given-names>A</given-names></name><name><surname>Trojanowski</surname> <given-names>JQ</given-names></name><name><surname>Shaw</surname> <given-names>LM</given-names></name><name><surname>Seibyl</surname> <given-names>J</given-names></name><name><surname>Singleton</surname> <given-names>A</given-names></name><name><surname>Toga</surname> <given-names>AW</given-names></name><name><surname>Galasko</surname> <given-names>D</given-names></name><name><surname>Foroud</surname> <given-names>T</given-names></name><name><surname>Tosun</surname> <given-names>D</given-names></name><name><surname>Poston</surname> <given-names>K</given-names></name><name><surname>Weintraub</surname> <given-names>D</given-names></name><name><surname>Mollenhauer</surname> <given-names>B</given-names></name><name><surname>Tanner</surname> <given-names>CM</given-names></name><name><surname>Kieburtz</surname> <given-names>K</given-names></name><name><surname>Chahine</surname> <given-names>LM</given-names></name><name><surname>Reimer</surname> <given-names>A</given-names></name><name><surname>Hutten</surname> <given-names>SJ</given-names></name><name><surname>Bressman</surname> <given-names>S</given-names></name><name><surname>Marek</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the parkinson's Progression Markers Initiative (PPMI): a cross-sectional study</article-title><source>The Lancet Neurology</source><volume>19</volume><fpage>71</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30319-9</pub-id><pub-id pub-id-type="pmid">31678032</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purlyte</surname> <given-names>E</given-names></name><name><surname>Dhekne</surname> <given-names>HS</given-names></name><name><surname>Sarhan</surname> <given-names>AR</given-names></name><name><surname>Gomez</surname> <given-names>R</given-names></name><name><surname>Lis</surname> <given-names>P</given-names></name><name><surname>Wightman</surname> <given-names>M</given-names></name><name><surname>Martinez</surname> <given-names>TN</given-names></name><name><surname>Tonelli</surname> <given-names>F</given-names></name><name><surname>Pfeffer</surname> <given-names>SR</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rab29 activation of the parkinson's disease-associated LRRK2 kinase</article-title><source>The EMBO Journal</source><volume>37</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.15252/embj.201798099</pub-id><pub-id pub-id-type="pmid">29212815</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roche</surname> <given-names>KW</given-names></name><name><surname>O'Brien</surname> <given-names>RJ</given-names></name><name><surname>Mammen</surname> <given-names>AL</given-names></name><name><surname>Bernhardt</surname> <given-names>J</given-names></name><name><surname>Huganir</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit</article-title><source>Neuron</source><volume>16</volume><fpage>1179</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(00)80144-0</pub-id><pub-id pub-id-type="pmid">8663994</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname> <given-names>A</given-names></name><name><surname>Macosko</surname> <given-names>EZ</given-names></name><name><surname>Wysoker</surname> <given-names>A</given-names></name><name><surname>Goldman</surname> <given-names>M</given-names></name><name><surname>Krienen</surname> <given-names>FM</given-names></name><name><surname>de Rivera</surname> <given-names>H</given-names></name><name><surname>Bien</surname> <given-names>E</given-names></name><name><surname>Baum</surname> <given-names>M</given-names></name><name><surname>Bortolin</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Goeva</surname> <given-names>A</given-names></name><name><surname>Nemesh</surname> <given-names>J</given-names></name><name><surname>Kamitaki</surname> <given-names>N</given-names></name><name><surname>Brumbaugh</surname> <given-names>S</given-names></name><name><surname>Kulp</surname> <given-names>D</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular diversity and specializations among the cells of the adult mouse brain</article-title><source>Cell</source><volume>174</volume><fpage>1015</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.028</pub-id><pub-id pub-id-type="pmid">30096299</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schier</surname> <given-names>CJ</given-names></name><name><surname>Marks</surname> <given-names>WD</given-names></name><name><surname>Paris</surname> <given-names>JJ</given-names></name><name><surname>Barbour</surname> <given-names>AJ</given-names></name><name><surname>McLane</surname> <given-names>VD</given-names></name><name><surname>Maragos</surname> <given-names>WF</given-names></name><name><surname>McQuiston</surname> <given-names>AR</given-names></name><name><surname>Knapp</surname> <given-names>PE</given-names></name><name><surname>Hauser</surname> <given-names>KF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Selective vulnerability of striatal D2 versus D1 dopamine Receptor-Expressing medium spiny neurons in HIV-1 tat transgenic male mice</article-title><source>The Journal of Neuroscience</source><volume>37</volume><fpage>5758</fpage><lpage>5769</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0622-17.2017</pub-id><pub-id pub-id-type="pmid">28473642</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname> <given-names>J</given-names></name><name><surname>Arganda-Carreras</surname> <given-names>I</given-names></name><name><surname>Frise</surname> <given-names>E</given-names></name><name><surname>Kaynig</surname> <given-names>V</given-names></name><name><surname>Longair</surname> <given-names>M</given-names></name><name><surname>Pietzsch</surname> <given-names>T</given-names></name><name><surname>Preibisch</surname> <given-names>S</given-names></name><name><surname>Rueden</surname> <given-names>C</given-names></name><name><surname>Saalfeld</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>B</given-names></name><name><surname>Tinevez</surname> <given-names>JY</given-names></name><name><surname>White</surname> <given-names>DJ</given-names></name><name><surname>Hartenstein</surname> <given-names>V</given-names></name><name><surname>Eliceiri</surname> <given-names>K</given-names></name><name><surname>Tomancak</surname> <given-names>P</given-names></name><name><surname>Cardona</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>KR</given-names></name><name><surname>Kopeikina</surname> <given-names>KJ</given-names></name><name><surname>Fawcett-Patel</surname> <given-names>JM</given-names></name><name><surname>Leaderbrand</surname> <given-names>K</given-names></name><name><surname>Gao</surname> <given-names>R</given-names></name><name><surname>Schürmann</surname> <given-names>B</given-names></name><name><surname>Myczek</surname> <given-names>K</given-names></name><name><surname>Radulovic</surname> <given-names>J</given-names></name><name><surname>Swanson</surname> <given-names>GT</given-names></name><name><surname>Penzes</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Psychiatric risk factor ANK3/ankyrin-G nanodomains regulate the structure and function of glutamatergic synapses</article-title><source>Neuron</source><volume>84</volume><fpage>399</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.10.010</pub-id><pub-id pub-id-type="pmid">25374361</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steger</surname> <given-names>M</given-names></name><name><surname>Tonelli</surname> <given-names>F</given-names></name><name><surname>Ito</surname> <given-names>G</given-names></name><name><surname>Davies</surname> <given-names>P</given-names></name><name><surname>Trost</surname> <given-names>M</given-names></name><name><surname>Vetter</surname> <given-names>M</given-names></name><name><surname>Wachter</surname> <given-names>S</given-names></name><name><surname>Lorentzen</surname> <given-names>E</given-names></name><name><surname>Duddy</surname> <given-names>G</given-names></name><name><surname>Wilson</surname> <given-names>S</given-names></name><name><surname>Baptista</surname> <given-names>MA</given-names></name><name><surname>Fiske</surname> <given-names>BK</given-names></name><name><surname>Fell</surname> <given-names>MJ</given-names></name><name><surname>Morrow</surname> <given-names>JA</given-names></name><name><surname>Reith</surname> <given-names>AD</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases</article-title><source>eLife</source><volume>5</volume><elocation-id>e12813</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.12813</pub-id><pub-id pub-id-type="pmid">26824392</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suarez</surname> <given-names>LM</given-names></name><name><surname>Alberquilla</surname> <given-names>S</given-names></name><name><surname>García-Montes</surname> <given-names>JR</given-names></name><name><surname>Moratalla</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Differential synaptic remodeling by dopamine in direct and indirect striatal projection neurons in Pitx3<sup>-/-</sup>Mice, a Genetic Model of Parkinson's Disease</article-title><source>The Journal of Neuroscience</source><volume>38</volume><fpage>3619</fpage><lpage>3630</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3184-17.2018</pub-id><pub-id pub-id-type="pmid">29483281</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surmeier</surname> <given-names>DJ</given-names></name><name><surname>Ding</surname> <given-names>J</given-names></name><name><surname>Day</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Shen</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons</article-title><source>Trends in Neurosciences</source><volume>30</volume><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2007.03.008</pub-id><pub-id pub-id-type="pmid">17408758</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>the Barcelona LRRK2 Study Group</collab><name><surname>Vilas</surname> <given-names>D</given-names></name><name><surname>Segura</surname> <given-names>B</given-names></name><name><surname>Baggio</surname> <given-names>HC</given-names></name><name><surname>Pont-Sunyer</surname> <given-names>C</given-names></name><name><surname>Compta</surname> <given-names>Y</given-names></name><name><surname>Valldeoriola</surname> <given-names>F</given-names></name><name><surname>José Martí</surname> <given-names>M</given-names></name><name><surname>Quintana</surname> <given-names>M</given-names></name><name><surname>Bayés</surname> <given-names>A</given-names></name><name><surname>Hernández-Vara</surname> <given-names>J</given-names></name><name><surname>Calopa</surname> <given-names>M</given-names></name><name><surname>Aguilar</surname> <given-names>M</given-names></name><name><surname>Junqué</surname> <given-names>C</given-names></name><name><surname>Tolosa</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Nigral and striatal connectivity alterations in asymptomatic <italic>LRRK2</italic> mutation carriers: a magnetic resonance imaging study</article-title><source>Movement Disorders</source><volume>31</volume><fpage>1820</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1002/mds.26799</pub-id><pub-id pub-id-type="pmid">27653520</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>X</given-names></name><name><surname>Kai</surname> <given-names>L</given-names></name><name><surname>Hockberger</surname> <given-names>PE</given-names></name><name><surname>Wokosin</surname> <given-names>DL</given-names></name><name><surname>Surmeier</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons</article-title><source>Molecular and Cellular Neuroscience</source><volume>44</volume><fpage>94</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2010.01.012</pub-id><pub-id pub-id-type="pmid">20197093</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname> <given-names>Y</given-names></name><name><surname>Pisani</surname> <given-names>A</given-names></name><name><surname>Martella</surname> <given-names>G</given-names></name><name><surname>Karouani</surname> <given-names>M</given-names></name><name><surname>Yamaguchi</surname> <given-names>H</given-names></name><name><surname>Pothos</surname> <given-names>EN</given-names></name><name><surname>Shen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice</article-title><source>PNAS</source><volume>106</volume><fpage>14622</fpage><lpage>14627</lpage><pub-id pub-id-type="doi">10.1073/pnas.0906334106</pub-id><pub-id pub-id-type="pmid">19667187</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tozzi</surname> <given-names>A</given-names></name><name><surname>Durante</surname> <given-names>V</given-names></name><name><surname>Bastioli</surname> <given-names>G</given-names></name><name><surname>Mazzocchetti</surname> <given-names>P</given-names></name><name><surname>Novello</surname> <given-names>S</given-names></name><name><surname>Mechelli</surname> <given-names>A</given-names></name><name><surname>Morari</surname> <given-names>M</given-names></name><name><surname>Costa</surname> <given-names>C</given-names></name><name><surname>Mancini</surname> <given-names>A</given-names></name><name><surname>Di Filippo</surname> <given-names>M</given-names></name><name><surname>Calabresi</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease</article-title><source>Neurobiology of Disease</source><volume>118</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.06.008</pub-id><pub-id pub-id-type="pmid">29908325</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tozzi</surname> <given-names>A</given-names></name><name><surname>Tantucci</surname> <given-names>M</given-names></name><name><surname>Marchi</surname> <given-names>S</given-names></name><name><surname>Mazzocchetti</surname> <given-names>P</given-names></name><name><surname>Morari</surname> <given-names>M</given-names></name><name><surname>Pinton</surname> <given-names>P</given-names></name><name><surname>Mancini</surname> <given-names>A</given-names></name><name><surname>Calabresi</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>204</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-017-0221-2</pub-id><pub-id pub-id-type="pmid">29434188</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilas</surname> <given-names>D</given-names></name><name><surname>Ispierto</surname> <given-names>L</given-names></name><name><surname>Álvarez</surname> <given-names>R</given-names></name><name><surname>Pont-Sunyer</surname> <given-names>C</given-names></name><name><surname>Martí</surname> <given-names>MJ</given-names></name><name><surname>Valldeoriola</surname> <given-names>F</given-names></name><name><surname>Compta</surname> <given-names>Y</given-names></name><name><surname>de Fabregues</surname> <given-names>O</given-names></name><name><surname>Hernández-Vara</surname> <given-names>J</given-names></name><name><surname>Puente</surname> <given-names>V</given-names></name><name><surname>Calopa</surname> <given-names>M</given-names></name><name><surname>Jaumà</surname> <given-names>S</given-names></name><name><surname>Campdelacreu</surname> <given-names>J</given-names></name><name><surname>Aguilar</surname> <given-names>M</given-names></name><name><surname>Quílez</surname> <given-names>P</given-names></name><name><surname>Casquero</surname> <given-names>P</given-names></name><name><surname>Lomeña</surname> <given-names>F</given-names></name><name><surname>Ríos</surname> <given-names>J</given-names></name><name><surname>Tolosa</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers</article-title><source>Parkinsonism &amp; Related Disorders</source><volume>21</volume><fpage>1170</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.08.007</pub-id><pub-id pub-id-type="pmid">26306001</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villalba</surname> <given-names>RM</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Smith</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys</article-title><source>Experimental Neurology</source><volume>215</volume><fpage>220</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2008.09.025</pub-id><pub-id pub-id-type="pmid">18977221</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volta</surname> <given-names>M</given-names></name><name><surname>Beccano-Kelly</surname> <given-names>DA</given-names></name><name><surname>Paschall</surname> <given-names>SA</given-names></name><name><surname>Cataldi</surname> <given-names>S</given-names></name><name><surname>MacIsaac</surname> <given-names>SE</given-names></name><name><surname>Kuhlmann</surname> <given-names>N</given-names></name><name><surname>Kadgien</surname> <given-names>CA</given-names></name><name><surname>Tatarnikov</surname> <given-names>I</given-names></name><name><surname>Fox</surname> <given-names>J</given-names></name><name><surname>Khinda</surname> <given-names>J</given-names></name><name><surname>Mitchell</surname> <given-names>E</given-names></name><name><surname>Bergeron</surname> <given-names>S</given-names></name><name><surname>Melrose</surname> <given-names>H</given-names></name><name><surname>Farrer</surname> <given-names>MJ</given-names></name><name><surname>Milnerwood</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice</article-title><source>eLife</source><volume>6</volume><elocation-id>e28377</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.28377</pub-id><pub-id pub-id-type="pmid">28930069</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volta</surname> <given-names>M</given-names></name><name><surname>Melrose</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis</article-title><source>Biochemical Society Transactions</source><volume>45</volume><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1042/BST20160238</pub-id><pub-id pub-id-type="pmid">28202664</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname> <given-names>AB</given-names></name><name><surname>Cowell</surname> <given-names>RM</given-names></name><name><surname>Daher</surname> <given-names>JP</given-names></name><name><surname>Moehle</surname> <given-names>MS</given-names></name><name><surname>Hinkle</surname> <given-names>KM</given-names></name><name><surname>Melrose</surname> <given-names>HL</given-names></name><name><surname>Standaert</surname> <given-names>DG</given-names></name><name><surname>Volpicelli-Daley</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Differential LRRK2 expression in the cortex, Striatum, and substantia nigra in transgenic and nontransgenic rodents</article-title><source>Journal of Comparative Neurology</source><volume>522</volume><fpage>2465</fpage><lpage>2480</lpage><pub-id pub-id-type="doi">10.1002/cne.23583</pub-id><pub-id pub-id-type="pmid">24633735</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Xenias</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pathogenic LRRK2 R1441C mutation is associated with striatal alterations</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.03.11.986455</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname> <given-names>L</given-names></name><name><surname>Priest</surname> <given-names>MF</given-names></name><name><surname>Nasenbeny</surname> <given-names>J</given-names></name><name><surname>Lu</surname> <given-names>T</given-names></name><name><surname>Kozorovitskiy</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Biased oxytocinergic modulation of midbrain dopamine systems</article-title><source>Neuron</source><volume>95</volume><fpage>368</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.06.003</pub-id><pub-id pub-id-type="pmid">28669546</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname> <given-names>L</given-names></name><name><surname>Priest</surname> <given-names>MF</given-names></name><name><surname>Kozorovitskiy</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oxytocin functions as a spatiotemporal filter for excitatory synaptic inputs to VTA dopamine neurons</article-title><source>eLife</source><volume>7</volume><elocation-id>e33892</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.33892</pub-id><pub-id pub-id-type="pmid">29676731</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Coombes</surname> <given-names>CE</given-names></name><name><surname>Kilaru</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Gitler</surname> <given-names>AD</given-names></name><name><surname>Bowers</surname> <given-names>WJ</given-names></name><name><surname>Dawson</surname> <given-names>VL</given-names></name><name><surname>Dawson</surname> <given-names>TM</given-names></name><name><surname>Moore</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>GTPase activity plays a key role in the pathobiology of LRRK2</article-title><source>PLOS Genetics</source><volume>6</volume><elocation-id>e1000902</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000902</pub-id><pub-id pub-id-type="pmid">20386743</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Dawson</surname> <given-names>TM</given-names></name><name><surname>Dawson</surname> <given-names>VL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Models of LRRK2-Associated parkinson's Disease</article-title><source>Advances in Neurobiology</source><volume>14</volume><fpage>163</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-49969-7_9</pub-id><pub-id pub-id-type="pmid">28353284</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname> <given-names>M</given-names></name><name><surname>Hinkle</surname> <given-names>KM</given-names></name><name><surname>Davies</surname> <given-names>P</given-names></name><name><surname>Trushina</surname> <given-names>E</given-names></name><name><surname>Fiesel</surname> <given-names>FC</given-names></name><name><surname>Christenson</surname> <given-names>TA</given-names></name><name><surname>Schroeder</surname> <given-names>AS</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Bowles</surname> <given-names>E</given-names></name><name><surname>Behrouz</surname> <given-names>B</given-names></name><name><surname>Lincoln</surname> <given-names>SJ</given-names></name><name><surname>Beevers</surname> <given-names>JE</given-names></name><name><surname>Milnerwood</surname> <given-names>AJ</given-names></name><name><surname>Kurti</surname> <given-names>A</given-names></name><name><surname>McLean</surname> <given-names>PJ</given-names></name><name><surname>Fryer</surname> <given-names>JD</given-names></name><name><surname>Springer</surname> <given-names>W</given-names></name><name><surname>Dickson</surname> <given-names>DW</given-names></name><name><surname>Farrer</surname> <given-names>MJ</given-names></name><name><surname>Melrose</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice</article-title><source>Neurobiology of Disease</source><volume>78</volume><fpage>172</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2015.02.031</pub-id><pub-id pub-id-type="pmid">25836420</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname> <given-names>S</given-names></name><name><surname>Shen</surname> <given-names>W</given-names></name><name><surname>Graves</surname> <given-names>SM</given-names></name><name><surname>Surmeier</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dopaminergic modulation of striatal function and Parkinson’s disease</article-title><source>Journal of Neural Transmission</source><volume>126</volume><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1007/s00702-019-01997-y</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Nagai</surname> <given-names>T</given-names></name><name><surname>Ahammad</surname> <given-names>RU</given-names></name><name><surname>Kuroda</surname> <given-names>K</given-names></name><name><surname>Nakamuta</surname> <given-names>S</given-names></name><name><surname>Nakano</surname> <given-names>T</given-names></name><name><surname>Yukinawa</surname> <given-names>N</given-names></name><name><surname>Funahashi</surname> <given-names>Y</given-names></name><name><surname>Yamahashi</surname> <given-names>Y</given-names></name><name><surname>Amano</surname> <given-names>M</given-names></name><name><surname>Yoshimoto</surname> <given-names>J</given-names></name><name><surname>Yamada</surname> <given-names>K</given-names></name><name><surname>Kaibuchi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Balance between dopamine and adenosine signals regulates the PKA/Rap1 pathway in striatal medium spiny neurons</article-title><source>Neurochemistry International</source><volume>122</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2018.10.008</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Antibody</td><td valign="top">Phospho-PKA Substrate <break/>(RRXS*/T*) (100G7E) rabbit monoclonal</td><td valign="top">Cell Signaling Technology</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331817">AB_331817</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">AMPA Receptor 1 (GluA1) (D4N9V) rabbit monoclonal</td><td valign="top">Cell Signaling Technology</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2732897">AB_2732897</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Phospho-AMPA Receptor 1 (GluA1) <break/>(Ser845) (D10G5) rabbit monoclonal</td><td valign="top">Cell Signaling Technology</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10860773">AB_10860773</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Synaptophysin rabbit polyclonal</td><td valign="top">Cell Signaling Technology</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1904154">AB_1904154</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-RAB8A antibody [EPR14873] rabbit monoclonal</td><td valign="top">Abcam</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2814989">AB_2814989</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">RAB8A (phospho T72) [MJF-R20] rabbit monoclonal</td><td valign="top">Abcam</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2814988">AB_2814988</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rab10 (D36C4) XP Rabbit mAb rabbit monoclonal</td><td valign="top">Cell signaling technology</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10828219">AB_10828219</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-RAB10 (phospho T73) antibody [MJF-R21] rabbit monoclonal</td><td valign="top">Abcam</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2811274">AB_2811274</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">HOMER1 polyclonal antibody rabbit polyclonal</td><td valign="top">Proteintech</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2295573">AB_2295573</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">GluA1/GluR1 glutamate receptor clone N355/1 <break/>mouse monoclonal</td><td valign="top">UC Davis/NIH NeuroMab Facility</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2315840">AB_2315840</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">PSD-95 monoclonal (6G6-1C9) mouse monoclonal</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_325399">AB_325399</ext-link></td><td valign="top">WB (1:1000) <break/>IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">PSD-95 polyclonal rabbit polyclonal</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_87705">AB_87705</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">GFP chicken polyclonal</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534023">AB_2534023</ext-link></td><td valign="top">IF (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mCherry (16D7) rat monoclonal</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2536611">AB_2536611</ext-link></td><td valign="top">IF (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2533947">AB_2533947</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2533967">AB_2533967</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_162542">AB_162542</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 568</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534017">AB_2534017</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 568</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534121">AB_2534121</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-Chicken IgY (H+L) Secondary Antibody, Alexa Fluor 488</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534096">AB_2534096</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488</td><td valign="top">Invitrogen</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2535792">AB_2535792</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Other</td><td valign="top">Fetal Bovine Serum</td><td valign="top">Sigma-Aldrich</td><td valign="top">F0926</td><td valign="top">5%</td></tr><tr><td valign="top">Other</td><td valign="top">Horse Serum, heat inactivated, New Zealand origin</td><td valign="top">Gibco</td><td valign="top">26050088</td><td valign="top">5%</td></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">Laminin Mouse Protein, Natural</td><td valign="top">Gibco</td><td valign="top">23017015</td><td valign="top">10 μg/ml</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Poly-D-lysine hydrobromide</td><td valign="top">Sigma</td><td valign="top">P0899</td><td valign="top">50 μg/ml</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">GlutaMAX Supplement (100x)</td><td valign="top">Gibco</td><td valign="top">35050061</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">B-27 Supplement (50X), serum free</td><td valign="top">Gibco</td><td valign="top">17504044</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">N-2 Supplement (100X)</td><td valign="top">Gibco</td><td valign="top">17502001</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Antibiotic Antimycotic Solution (100×), Stabilized</td><td valign="top">Sigma-Aldrich</td><td valign="top">A5955</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Basal Medium Eagle</td><td valign="top">Sigma-Aldrich</td><td valign="top">B1522</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cytosine β-D-arabinofuranoside</td><td valign="top">Sigma-Aldrich</td><td valign="top">C1768</td><td valign="top">2.5 μM</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">PDS Kit, Papain Vial</td><td valign="top">Worthington Biochemical Corporation</td><td valign="top">LK003178</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DNase Vial (D2)</td><td valign="top">Worthington Biochemical Corporation</td><td valign="top">LK003172</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Sucrose</td><td valign="top">Sigma-Aldrich</td><td valign="top">S7903</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">HEPES solution</td><td valign="top">Sigma-Aldrich</td><td valign="top">H0887</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">UltraPure 1M Tris-HCI, pH 8.0</td><td valign="top">Invitrogen</td><td valign="top">15568025</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">MgCl2</td><td valign="top">Sigma-Aldrich</td><td valign="top">M8266</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Calcium chloride solution</td><td valign="top">Sigma-Aldrich</td><td valign="top">21115</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Triton X-100</td><td valign="top">Sigma-Aldrich</td><td valign="top">X100</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Ethylenediaminetetraacetic acid disodium salt solution</td><td valign="top">Sigma-Aldrich</td><td valign="top">E7889</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Halt Protease and Phosphatase Inhibitor Cocktail, EDTA-free (100X)</td><td valign="top">Thermo Scientific</td><td valign="top">78441</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Tris Buffered Saline (10x)</td><td valign="top">Sigma-Aldrich</td><td valign="top">T5912</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TWEEN 20</td><td valign="top">Sigma-Aldrich</td><td valign="top">P1379</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">MNI-L-glutamate</td><td valign="top">Tocris</td><td valign="top">1490</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/antibody/secondary/query/alexa+594">Alexa Fluor 594</ext-link></td><td valign="top">Thermo Fisher Scientific</td><td valign="top">A10438</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Sodium chloride</td><td valign="top">Sigma-Aldrich</td><td valign="top">S3014</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Potassium chloride</td><td valign="top">Sigma-Aldrich</td><td valign="top">P9541</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Sodium bicarbonate</td><td valign="top">Sigma-Aldrich</td><td valign="top">S5761</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Sodium phosphate monobasic</td><td valign="top">Sigma-Aldrich</td><td valign="top">S3139</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Calcium chloride</td><td valign="top">Sigma-Aldrich</td><td valign="top">C5670</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">D-(+)-Glucose</td><td valign="top">Sigma-Aldrich</td><td valign="top">G7021</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cesium methanesulfonate</td><td valign="top">Sigma-Aldrich</td><td valign="top">C1426</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cesium chloride</td><td valign="top">Sigma-Aldrich</td><td valign="top">C3032</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">HEPES</td><td valign="top">Sigma-Aldrich</td><td valign="top">54457</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid</td><td valign="top">Sigma-Aldrich</td><td valign="top">E3889</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Gabazine/SR 95531 hydrobromide</td><td valign="top">Tocris</td><td valign="top">1262</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Scopolamine hydrobromide</td><td valign="top">Tocris</td><td valign="top">1414</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Phosphocreatine disodium salt hydrate</td><td valign="top">Sigma-Aldrich</td><td valign="top">P7936</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">QX-314 Chloride</td><td valign="top">Tocris</td><td valign="top">2313</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Adenosine 5’-triphosphate magnesium salt</td><td valign="top">Sigma-Aldrich</td><td valign="top">A9187</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Guanosine 5’-triphosphate sodium salt hydrate</td><td valign="top">Sigma-Aldrich</td><td valign="top">51120</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">(R)-CPP</td><td valign="top">Tocris</td><td valign="top">0247</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Tetrodotoxin</td><td valign="top">Tocris</td><td valign="top">1078</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Potassium gluconate</td><td valign="top">Sigma-Aldrich</td><td valign="top">1550001</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">iBlot Transfer Stack, nitrocellulose, regular size</td><td valign="top">Invitrogen</td><td valign="top">IB301031</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NuPAGE 4–12% Bis-Tris Protein Gels, 1.5 mm, 15-well</td><td valign="top">Invitrogen</td><td valign="top">NP0336BOX</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NuPAGE MES SDS Running Buffer (20X)</td><td valign="top">Invitrogen</td><td valign="top">NP0002</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NuPAGE Antioxidant</td><td valign="top">Invitrogen</td><td valign="top">NP0005</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NuPAGE Transfer Buffer (20X)</td><td valign="top">Invitrogen</td><td valign="top">NP0006</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NuPAGE LDS Sample Buffer (4X)</td><td valign="top">Invitrogen</td><td valign="top">NP0008</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NuPAGE Sample Reducing Agent (10X)</td><td valign="top">Invitrogen</td><td valign="top">NP0009</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Pierce BCA Protein Assay Kit</td><td valign="top">Thermo Scientific</td><td valign="top">23225</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Restore Western Blot Stripping Buffer</td><td valign="top">Thermo Scientific</td><td valign="top">21059</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">ProLong Diamond Antifade Mountant with DAPI</td><td valign="top">Invitrogen</td><td valign="top">P36971</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">BLUeye Prestained Protein Ladder</td><td valign="top">Sigma-Aldrich</td><td valign="top">94964</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Immobilon ECL Ultra Western HRP Substrate</td><td valign="top">Millipore</td><td valign="top">WBULS0500</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad Prism 7</td><td valign="top">GraphPad Software Inc</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">NIS-elements 5.10</td><td valign="top">Nikon Instruments Inc</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014329">SCR_014329</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Imaris 9.21</td><td valign="top">Bitplane Inc</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_007370">SCR_007370</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">iBright Analysis Software</td><td valign="top">Thermo Scientific</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_017632">SCR_017632</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MATLAB</td><td valign="top">MathWorks</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_001622">SCR_001622</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FIJI</td><td valign="top"><xref ref-type="bibr" rid="bib47">Schindelin et al., 2012</xref></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://fiji.sc/">http://fiji.sc/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002285">SCR_002285</ext-link></td><td valign="top"/></tr><tr><td valign="top">Strain, strain background</td><td valign="top">rAAV8/Flex-GFP</td><td valign="top">UNC GTC vector core</td><td valign="top">Lot, AV4910B</td><td valign="top"/></tr></tbody></table></table-wrap></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58997.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Lupica</surname><given-names>Carl</given-names></name><role>Reviewing Editor</role><aff><institution>National Institute on Drug Abuse, National Institutes of Health</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Lupica</surname><given-names>Carl</given-names> </name><role>Reviewer</role><aff><institution>National Institute on Drug Abuse, National Institutes of Health</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Beckstead</surname><given-names>Michael J</given-names></name><role>Reviewer</role><aff><institution>Oklahoma Medical Research Foundation</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The reviewers felt that your study nicely integrated several approaches to compare indirect and direct striatal output pathways, and to show distinctions in these pathways in 2 LRRK2 mutations.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Pathway-specific deregulation of striatal excitatory synapses in LRRK2 mutations&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, including Carl Lupica as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by John Huguenard as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Michael J Beckstead (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Summary:</p><p>This is a report on the effects of 2 common LRRK2 gain of function mutations expressed in mouse lines on the properties of striatal neurons comprising either indirect (iSPNs) or direct pathway projections (dSPNs). The authors use structured illumination super-resolution and 2-photon microscopy, patch clamp electrophysiology, and Western blots to explore the effects of the GS and RC LRRK2 mutations on striatal synapses. Both structural and functional changes are identified, and there are differences reported both between the types of LRRK2 mutations and between indirect and direct striatal pathways. More specifically, the authors observe increased expression and altered organization of glutamatergic AMPA receptors in LRRK2 mutants and an associated decreased in the frequency of EPSCs at these synapses. This was accompanied by changes in the nano-architecture of dendritic spines and ionotropic currents activated with 2-photon glutamate uncaging. In general, the reviewers felt that the study nicely integrates several approaches to evaluate and compare how indirect and direct striatal output pathway synapses are altered in 2 relevant LRRK2 mutations. The attention to both functional and structural changes within these pathways represents a significant experimental advance in our understanding of the implications of LRKK2 and its role in heritable Parkinson's disease.</p><p>Revisions:</p><p>1) Results, paragraph one. This information regarding Rab8A isn't very clear. Has the Rab8A protein been identified in SPNs previously? If not, then its identification should be reported first, followed by the description of experiments showing its phosphorylation in the mutant mice.</p><p>2) Results, subsection “Pathway specific functional alterations in the synapses of R1441C and G2019S SPNs”. The sentence describing differences in mEPSC frequency for the mutant mice in the dSPN pathway should be reworded for clarity. In this instance, the frequency was lower than the control genotype. However, the authors are using the word &quot;decreased&quot; as a noun, indicating that a change was observed within an experiment, which is clearly not the case.</p><p>3) In the same subsection the authors should indicate that no changes in &quot;mean mEPSC&quot; amplitudes were noted because they report below that changes were observed in subsets of these mEPSCs.</p><p>4) Results, subsection “Pathway specific functional alterations in the synapses of R1441C and G2019S SPNs”, last sentences. The authors report that whereas no changes in averaged mEPSC amplitudes were noted across genotypes, there were changes in subsets of these events that could be discerned using cumulative amplitude distributions. A satisfactory exploration of this is central to the work because of the complex relationship between GluA1 (increased) and the changes in mEPSC frequency (decreased) and amplitude (maybe an increase?) reported by the authors. Currently, the change in mEPSC amplitude is not clear from the way these data are presented in Figure 4, and the statistical evaluation of these data (K-S- test with Bonferroni post-hoc) does not permit an evaluation of where in the distribution of amplitudes these changes occur. The changes in amplitude distribution would best be evaluated by re-plotting the data using non-cumulative amplitude histograms for individual cells (or groups), and by estimating mean mEPSC amplitude modes using either Gaussian, or other statistical curves that fit the data more appropriately. Non-cumulative histograms should then be shown to demonstrate the differences in mEPSC sub-sets, and the number of cells showing a significant shift toward larger amplitude mEPSCs should be reported.</p><p>5) The statistical handling of the data in Figures 1F, 1G, and Figure 1—figure supplement 1C is inappropriate. Normalizing to the mean of the control group and getting rid of the error bar in that group negates a potentially important source of error. Use of a non-parametric analysis does not mitigate this concern. These data should be reanalyzed and re-graphed with the actual ratio values, which are already normalized to PSD95 or Homer1 expression. Sample sizes here were low, therefore this could require running additional samples if certain results drop out of significance upon re-analysis.</p><p>6) Currently, the discussion is very LRRK2-centric and doesn't venture as it should outside of models with this gene to larger questions concerning PD and basal ganglia circuitry, therefore it's not entirely clear where this work fits in with the larger field. Conspicuously absent is any link between this work and what is known about the direct and indirect pathway SPNs in PD. The discussion would therefore benefit from information previously published with regard to PD in humans or in animal models integrated with the present work.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your article &quot;Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations&quot; for consideration by <italic>eLife</italic>.</p><p>Summary:</p><p>In this revision the authors have made several changes in-line with comments from the earlier review and this has improved the manuscript. However, an issue remains with the implementation of curvilinear fits to the mEPSC data that should be addressed.</p><p>Revisions:</p><p>1) Figure 4 and Figure 4—figure supplement 1 and Materials and methods: A description of how the Gaussian fits were obtained as well as the statistical analysis that was used to evaluate them should be included in the Materials and methods.</p><p>2) Figure 4—figure supplement 1: &quot;Bin Center&quot; is not an adequate label. This should be re-labeled either &quot;Amplitude (pA)&quot; or &quot;Bin center (pA). Additionally, the pertinent data for these fits (mean amplitude, S.D. or S.E.M.) and goodness of fit information should be provided.</p><p>3) Figure 4—figure supplement 1: Why are the complete gaussian curves not shown? It is the peak of the inverted U-shaped curve that defines the mean amplitude of the responses falling into that bin. This is not easily observed without the full curve. Also, the means and errors (SEM or SD) of the amplitudes defined by the Gaussian curves should be given.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58997.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Revisions:</p><p>1) Results, paragraph one. This information regarding Rab8A isn't very clear. Has the Rab8A protein been identified in SPNs previously? If not, then its identification should be reported first, followed by the description of experiments showing its phosphorylation in the mutant mice.</p></disp-quote><p>To highlight the increase in LRRK2 kinase function in the RC genotype mice we now have examined another LRRK2 substrate, a protein Rab10 that is part of the same family as Rab8A and is reported to be expressed in the striatum (e.g., Allen Brain Atlas, Dropviz).</p><p>We have also added an acknowledgement that Rab8A has not been extensively characterized in the striatum; however, low expression of Rab8A RNA has been reported in single cell sources like Dropviz, and our data show moderate expression of a band likely corresponding to p-Rab8A/total Rab8A (which is also increased in the RC genotype). Therefore, with the newly added data for Rab10 phosphorylation showing a similar trend to p-Rab8A, we have decided to keep both LRRK2 targets in this figure. Results paragraph one and Figure 1D.</p><disp-quote content-type="editor-comment"><p>2) Results, subsection “Pathway specific functional alterations in the synapses of R1441C and G2019S SPNs”. The sentence describing differences in mEPSC frequency for the mutant mice in the dSPN pathway should be reworded for clarity. In this instance, the frequency was lower than the control genotype. However, the authors are using the word &quot;decreased&quot; as a noun, indicating that a change was observed within an experiment, which is clearly not the case.</p></disp-quote><p>Reworded for clarity in the sentence noted by the reviewer, as well as in the following sentences.</p><disp-quote content-type="editor-comment"><p>3) In the same subsection the authors should indicate that no changes in &quot;mean mEPSC&quot; amplitudes were noted because they report below that changes were observed in subsets of these mEPSCs.</p></disp-quote><p>Reworded as requested.</p><disp-quote content-type="editor-comment"><p>4) Results, subsection “Pathway specific functional alterations in the synapses of R1441C and G2019S SPNs”, last sentences. The authors report that whereas no changes in averaged mEPSC amplitudes were noted across genotypes, there were changes in subsets of these events that could be discerned using cumulative amplitude distributions. A satisfactory exploration of this is central to the work because of the complex relationship between GluA1 (increased) and the changes in mEPSC frequency (decreased) and amplitude (maybe an increase?) reported by the authors. Currently, the change in mEPSC amplitude is not clear from the way these data are presented in Figure 4, and the statistical evaluation of these data (K-S- test with Bonferroni post-hoc) does not permit an evaluation of where in the distribution of amplitudes these changes occur. The changes in amplitude distribution would best be evaluated by re-plotting the data using non-cumulative amplitude histograms for individual cells (or groups), and by estimating mean mEPSC amplitude modes using either Gaussian, or other statistical curves that fit the data more appropriately. Non-cumulative histograms should then be shown to demonstrate the differences in mEPSC sub-sets, and the number of cells showing a significant shift toward larger amplitude mEPSCs should be reported.</p></disp-quote><p>We have carried out the analyses for mEPSC amplitudes as suggested by the reviewer. We added the plots of non-cumulative histograms of response amplitudes, and kept the cumulative distributions as a small inset, for those familiar with this way of representing the data. K-S tests were removed for both amplitude and frequency analyses. We have compared Gaussian fits to the amplitude histograms across cell class and genotype, reporting the results in the main text and new Figure 4—figure supplement 1 showing the fits. These analyses confirm the shift towards larger events selectively in the GFP-negative SPNs of the RC genotype. Subsection “Pathway specific functional alterations in the synapses of R1441C and G2019S SPNs”, (Figure 4D, Figure 4—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>5) The statistical handling of the data in Figures 1F, 1G, and S1C is inappropriate. Normalizing to the mean of the control group and getting rid of the error bar in that group negates a potentially important source of error. Use of a non-parametric analysis does not mitigate this concern. These data should be reanalyzed and re-graphed with the actual ratio values, which are already normalized to PSD95 or Homer1 expression. Sample sizes here were low, therefore this could require running additional samples if certain results drop out of significance upon re-analysis.</p></disp-quote><p>Based on the reviewer’s recommendation, we ran two additional samples (for n=6), and we have graphed the data with the actual values normalized to PSD95 expression. The conclusions from this re-analysis remain the same. In addition, we have re-plotted the data of the PSD95/Homer normalization showing their values rather than the normalized mean of the control group. Results paragraph one, Figure 1F, G and Figure 1—figure supplement 1B, C.</p><disp-quote content-type="editor-comment"><p>6) Currently, the discussion is very LRRK2-centric and doesn't venture as it should outside of models with this gene to larger questions concerning PD and basal ganglia circuitry, therefore it's not entirely clear where this work fits in with the larger field. Conspicuously absent is any link between this work and what is known about the direct and indirect pathway SPNs in PD. The Discussion would therefore benefit from information previously published with regard to PD in humans or in animal models integrated with the present work.</p></disp-quote><p>We have added a new paragraph at the end of the Discussion where we place the data in a broader context.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Revisions:</p><p>1) Figure 4 and Figure 4—figure supplement 1 and Materials and methods: A description of how the Gaussian fits were obtained as well as the statistical analysis that was used to evaluate them should be included in the Materials and methods.</p></disp-quote><p>We fit the data with a gamma distribution, a non-negative asymmetrical distribution, because the mEPSC amplitude data were not normally or lognormally distributed (failing D'Agostino and Pearson, Shapiro-Wilk, and KS normality tests, p-values &lt; 0.0001, alpha=0.05, for both raw and log-transformed data). Skew and kurtosis across the 6 datasets were 2.19±0.16 and 6.34±0.1, respectively, appropriate the gamma distribution.</p><p>For further comparison, continuous Gaussian and gamma distributions were fitted to the EPSC amplitude data by genotype and cell type using fitdist function in fitdistrplus library in R with the maximum likelihood estimation method. The Akaike information criterion (AIC) values were reported as goodness-of-fit criteria. The lower AIC values suggested a more appropriate fit using gamma distribution, which was overlayed in the histogram with bin width=1pA (Figure 4—figure supplement 1A).</p><table-wrap id="resptable1" position="anchor"><label>Author response table 1.</label><table frame="hsides" rules="groups"><thead><tr><th>Genotype/ <break/>Cell-type</th><th>Gaussian/ <break/>Normal AIC</th><th>Gamma AIC</th></tr></thead><tbody><tr><td><italic>BAC, GFP-</italic></td><td>13166.75</td><td>11812.54</td></tr><tr><td><italic>RC, GFP-</italic></td><td>8252.910</td><td>7721.240</td></tr><tr><td><italic>GS, GFP-</italic></td><td>5373.360</td><td>4919.803</td></tr><tr><td><italic>BAC, GFP+</italic></td><td>10312.09</td><td>9476.535</td></tr><tr><td><italic>RC.GFP+</italic></td><td>7324.117</td><td>6825.080</td></tr><tr><td><italic>GS, GFP+</italic></td><td>5305.298</td><td>4880.877</td></tr></tbody></table></table-wrap><p>To compare whether each distribution is statistically significantly different, we estimated the means of mEPSC amplitudes across different genotypes for GFP- and GFP+ neurons types using generalized linear modeling (GLM) with a gamma family distribution. All coefficients were statistically significant and were kept for posthoc pairwise comparison. To test whether mEPSC amplitudes differ across genotype by cell type, we used emmeans R package to summarize the estimated mean of EPSC amplitudes and applied Bonferroni correction at a confidence level alpha=0.05. Estimated responses (i.e., fitted mEPSC amplitude) were reported along with the corresponding lower and upper 95% confidence intervals (Figure 4—figure supplement 1B). Bonferroni corrected posthoc comparisons indicated that mEPSC amplitudes differ across genotype in GFP-, but not GFP+ neurons.</p><disp-quote content-type="editor-comment"><p>2) Figure 4—figure supplement 1: &quot;Bin Center&quot; is not an adequate label. This should be re-labeled either &quot;Amplitude (pA)&quot; or &quot;Bin center (pA). Additionally, the pertinent data for these fits (mean amplitude, S.D. or S.E.M.) and goodness of fit information should be provided.</p></disp-quote><p>Figure 4—figure supplement 1 has been replaced, with posthoc amplitude mean comparisons and goodness of fit information provided in the legend, along with details in the Materials and methods section.</p><disp-quote content-type="editor-comment"><p>3) Figure 4—figure supplement 1: Why are the complete gaussian curves not shown? It is the peak of the inverted U-shaped curve that defines the mean amplitude of the responses falling into that bin. This is not easily observed without the full curve. Also, the means and errors (SEM or SD) of the amplitudes defined by the Gaussian curves should be given.</p></disp-quote><p>Updated curve fits are now shown (1) overlaid on the amplitude histogram for each genotype/cell type combination and (2) separately with the family of curves in Figure 4—figure supplement 1A. Amplitude estimates defined by GLM with gamma distribution are provided in Figure 4—figure supplement 1B.</p><p>The <xref ref-type="table" rid="resptable2">Author response table 2</xref> summarized the means and errors (SE) of amplitudes, fitted by the GLM model:</p><table-wrap id="resptable2" position="anchor"><label>Author response table 2.</label><table frame="hsides" rules="groups"><thead><tr><th>Cell type</th><th>Genotype</th><th>Mean amplitude (pA)</th><th>SE</th><th>LCL*</th><th>UCL*</th></tr></thead><tbody><tr><td>GFP-</td><td><italic>+/+ (BAC)</italic></td><td>9.33</td><td>0.106</td><td>9.08</td><td>9.59</td></tr><tr><td/><td><italic>+/GS</italic></td><td>8.26</td><td>0.138</td><td>7.95</td><td>8.61</td></tr><tr><td/><td><italic>+/RC</italic></td><td>10.11</td><td>0.143</td><td>9.78</td><td>10.47</td></tr><tr><td>GFP+</td><td><italic>+/+ (BAC)</italic></td><td>8.91</td><td>0.110</td><td>8.66</td><td>9.19</td></tr><tr><td/><td><italic>+/GS</italic></td><td>8.69</td><td>0.148</td><td>8.35</td><td>9.06</td></tr><tr><td/><td><italic>+/RC</italic></td><td>8.89</td><td>0.128</td><td>8.60</td><td>9.21</td></tr></tbody></table></table-wrap><p>*LCL and UCL are 95% lower and upper confidence limits.</p><p>Bonferroni-corrected p values for posthoc comparisons between genotypes for each cell type:</p><table-wrap id="resptable3" position="anchor"><label>Author response table 3.</label><table frame="hsides" rules="groups"><thead><tr><th>Cell type</th><th>Comparison</th><th>Bonferroni corrected p-values</th></tr></thead><tbody><tr><td>GFP-</td><td><italic>+/+ vs GS</italic></td><td>&lt; 0.0001</td></tr><tr><td/><td><italic>+/+ vs RC</italic></td><td>&lt; 0.0001</td></tr><tr><td/><td><italic>GS vs RC</italic></td><td>&lt; 0.0001</td></tr><tr><td>GFP+</td><td><italic>+/+ vs GS</italic></td><td>0.7070</td></tr><tr><td/><td><italic>+/+ vs RC</italic></td><td>1.0000</td></tr><tr><td/><td><italic>GS vs RC</italic></td><td>0.9278</td></tr></tbody></table></table-wrap><p>Besides the addition of a new Figure 4—figure supplement 1, the changes described above are now incorporated in the text (subsection “Pathway specific functional alterations in the synapses of R1441C and G2019S SPNs”), Materials and methods (Statistical analyses), and new Figure 4—figure supplement 1 legend.</p></body></sub-article></article>